Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 4142. Отображено 100.
07-06-2012 дата публикации

Purified Ethyl Ester Sophorolipid for the Treatment of Sepsis

Номер: US20120142621A1
Автор: George Falus, John Aikens, Maja Nowakowski, Martin Bluth
Принадлежит: Biomedica Management Corp

A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola . The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then decanted as a dense oil from the culture broth, subsequently washed to remove free fatty acids. Secondary chemical transformation via base catalyzed hydrolysis is used to reduce the 8 possible structural sophorolipid species to a single moiety, the 17-L-[(2′-O-b-D-glucopyranosyl-b-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de-acetylated free acid. The compound acts primarily through decreasing inflammatory cytokines and eliciting other synergistic anti-inflammatory mechanisms by blocking TLR4-CD14 upstream of the inflammatory signaling cascade. The compound can be administered either intraperitoneally or intravenously at single or multiple doses of 5-30 mg/kg of weight in solvent media or in capped nanoparticles, preferably within 48 hours of sepsis inception.

Подробнее
Номер записи: 1
13-09-2012 дата публикации

Virucidal properties of various forms of sophorolipids

Номер: US20120231068A1
Автор: Gustavo Doncel, Richard A. Gross, Vishal Shah
Принадлежит: Polytechnic Institute of NYU

A method for neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having antiviral properties produced by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as an antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an antiviral agent, and sophorolipid compounds for use as antiviral agents.

Подробнее
Номер записи: 2
18-10-2012 дата публикации

Assay for vitamin b12 absorption and method of making labeled vitamin b12

Номер: US20120264174A1
Автор: Bruce A. Buchholz, Colleen Carkeet, John Roth, Joshua Miller, Peter J. Anderson, Ralph Green, Stephen Dueker
Принадлежит: UNIVERSITY OF CALIFORNIA

The invention provides methods for labeling vitamin B12 with 14 C, 13 C, tritium, and deuterium. When radioisotopes are used, the invention provides for methods of labeling B12 with high specific activity. The invention also provides labeled vitamin B12 compositions made in accordance with the invention.

Подробнее
Номер записи: 3
06-12-2012 дата публикации

Sophorolipid transporter protein

Номер: US20120311741A1
Автор: Inge Van Bogaert, Wim Soetaert
Принадлежит: Individual

The invention relates to a transporter protein involved in the transport of sophorolipids. More specifically, it relates to a Candida bombicola sophorolipid transporter protein, and the use of this transporter to modulate the secretion and/or production of glycolipids, preferably sophorolipids in organisms, preferably in fungi.

Подробнее
Номер записи: 4
07-02-2013 дата публикации

Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids

Номер: US20130035403A1
Автор: Anja Thiessenhusen, Mirja Wessel, Steffen Schaffer
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Подробнее
Номер записи: 5
18-04-2013 дата публикации

NEW KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN

Номер: US20130096078A1
Автор: Park Je Won, Park Sung Ryeol, Sohng Jae Kyung, Yoon Yeo Joon
Принадлежит: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved. 1. A vector comprising at least one gene set selected from the group consisting of:(1) kanA, kanB, and kanK;(2) kanA, kanB, kanK, and kanF;(3) kanA, kanB, kanK, kanF, and kacA;(4) kanA, kanB, kanK, kanF, kacA, kanC, and kanD;(5) kanA, kanB, kanK, kanF, kacA, kanI, and kacL;(6) kanA, kanB, kanK, kanF, kacA, and kanE;(7) kanA, kanB, kanK, kanF, kacA, kanE, kanC, and kanD;(8) kanA, kanB, kanK, kanF, kacA, kanE, kanI, and kacL;(9) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, and kacL;(10) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;(11) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, kacL, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;(12) kanA, kanB, kanK, and nemD;(13) kanA, kanB, kanK, nemD, kacA, kanE, kanC, and kanD;(14) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, and kacL;(15) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, kacL, aprD3, and aprD4;(16) kanA, kanB, kanK, nemD, kacA, tobM2, kanC, kanD, kanI, kacL, aprD3, and aprD4;(17) kanA, kanB, kanK, and tobM1;(18) kanA, kanB, kanK, tobM1, kacA, kanE, kanC, and kanD;(19) kanA, kanB, kanK, and gtmG; and(20) kanA, kanB, kanK, gtmG, kacA, kanE, kanC, and kanD.2Streptomyces kanamyceticusStreptomyces tenebrariusBacillus circulansStreptomyces fradiaeMicromonospora echinospora.. The vector of claim 1 , wherein the kanA claim 1 , kanB claim 1 , kanK claim 1 , kanF claim 1 , kacA claim 1 , kanE claim 1 , kanC claim 1 , ...

Подробнее
Номер записи: 6
23-05-2013 дата публикации

Cells and methods for producing rhamnolipids

Номер: US20130130319A1
Автор: Anja Thiessenhusen, Mirja Wessel, Nadine Stein, Steffen Schaffer
Принадлежит: EVONIK GOLDSCHMIDT GMBH

The invention relates to cells and nucleic acids and also use thereof for producing rhamnolipids, and also methods for producing rhamnolipids.

Подробнее
Номер записи: 7
30-05-2013 дата публикации

SEMI-CONTINUOUS AND CONTINUOUS ENZYMATIC HYDROLYSIS PROCESS

Номер: US20130137143A1
Автор: Beney Pascal, Gallou Fabrice
Принадлежит: Anadys Pharmaceuticals, Inc.

The present invention relates to a semi-continuous or continuous process for the regioselective enzymatic hydrolysis of alcohol groups protected e.g. as esters or amino-acid esters or phosphate groups. The process of the present invention is useful for instance for the selective enzymatic hydrolysis of pyranosides or furanosides having more than one hydrolysable groups. 2. The process according to claim 1 , wherein the substrate is in a buffered solution having a pH of 5.5 to 7.5.3. The process according to claim 2 , wherein the buffered solution comprises a phosphate buffer claim 2 , an ammonium buffer claim 2 , a carbonate buffer claim 2 , or an acetate buffer.4. The process according to claim 3 , wherein the buffered solution comprises a phosphate buffer.5. The process according to claim 2 , wherein the buffered solution is passed through the immobilized enzyme at a rate of 0.1 mL/min to 50 mL/min.7. The process according to claim 6 , wherein the substrate is in a buffered solution having a pH of 5.5 to 7.5.8. The process according to claim 7 , wherein the buffered solution comprises a phosphate buffer claim 7 , an ammonium buffer claim 7 , a carbonate buffer claim 7 , or an acetate buffer.9. The process according to claim 8 , wherein the buffered solution comprises a phosphate buffer.10. The process according to claim 9 , wherein the buffered solution is passed through the immobilized enzyme at a rate of 0.1 mL/min to 50 mL/min.12. The process according to claim 11 , wherein the buffered solution comprises a phosphate buffer claim 11 , an ammonium buffer claim 11 , a carbonate buffer claim 11 , or an acetate buffer.13. The process according to claim 12 , wherein the buffered solution comprises a phosphate buffer.14. The process of claim 13 , wherein the buffered solution is passed through the immobilized enzyme at a rate of 0.1 mL/min to 50 mL/min.15. The process of claim 13 , wherein the phosphate buffered solution is passed through the immobilized enzyme at a ...

Подробнее
Номер записи: 8
25-07-2013 дата публикации

Methods of Ganglioside Production

Номер: US20130190257A1
Автор: Vandana Madanlal Sharma, Vanessa Ragaglia
Принадлежит: Garnet BioTherapeutics Inc

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

Подробнее
Номер записи: 9
22-08-2013 дата публикации

NOVEL FUCOSYLTRANSFERASES AND THEIR APPLICATIONS

Номер: US20130217068A1
Автор: Elling Lothar, Engels Leonie, Hüfner Eric, Jennewein Stefan, Parkot Julia
Принадлежит: JENNEWEIN BIOTECHNOLOGIE GMBH

The present invention relates to nucleic acid and amino acid sequences from and from , coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose. 1. Isolated polynucleotide encoding a polypeptide with alpha-1 ,3-fucosyltransferase activity and comprising a nucleic acid sequence selected from the group consisting of:a) SEQ ID Nos. 1, 3, or 5 of the attached sequence listing;b) a nucleic acid sequence complementary to SEQ ID Nos. 1, 3, or 5;c) nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequences defined in a) and b) or their complementary strands.2. The isolated polynucleotide of consisting of the SEQ ID Nos. 1 claim 1 , 3 claim 1 , or 5 encoding a polypeptide with alpha-1 claim 1 ,3 fucosyltransferase activity.3. Vector claim 1 , containing a nucleic acid sequence as claimed in encoding a polypeptide with alpha-1 claim 1 ,3-fucosyltransferase activity claim 1 , the nucleic acid sequence being operably linked to control sequences recognized by a host cell transformed with the vector.4. An isolated polypeptide with alpha-1 claim 1 ,3-fucosyltransferase activity consisting of an amino acid sequence selected from the group consisting of:(a) an amino acid sequence shown in SEQ ID NO. 2, 4, or 6;b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID No. 2, 4, or 6, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID Nos. 1, 3, or 5;c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID No. 2, 4, or 6, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a ...

Подробнее
Номер записи: 10
03-10-2013 дата публикации

Methods of Ganglioside Production

Номер: US20130261067A1
Автор: RAGAGLIA Vanessa, Sharma Vandana Madanlal
Принадлежит:

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. The method of claim 5 , wherein said fibroblast cell is a fibroblast from a human with GM1 gangliosidosis.8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

Подробнее
Номер записи: 11
10-10-2013 дата публикации

Novel phytochemicals from extracts of maple syrups and maple trees and uses thereof

Номер: US20130267474A1
Автор: Genevieve Beland, Julie Barbeau, Liya Li, Navindra P. Seeram
Принадлежит: FEDERATION DES PRODUCTEURS ACERICOLES DU QUEBEC, Rhode Island University

The present invention describes phytochemicals present in maple syrup and maple tree extracts by butanol, ethyl acetate and methanol. Novel compounds are isolated from maple syrups, including one compound Quebecol generated in the maple syrup manufacturing process. Also described are digesting extract of maple syrup. The phytochemicals may be used for the treatment or prevention of cancers, metabolic syndromes, diabetes, microorganism infections and/or antioxidants.

Подробнее
Номер записи: 12
17-10-2013 дата публикации

METHOD OF PRODUCING COMPOUND ORIGINATING FROM POLYSACCHARIDE-BASED BIO-MASS

Номер: US20130273608A1
Автор: Hanakawa Masayuki, Kurihara Hiroyuki, Minegishi Shinichi
Принадлежит:

A method of producing a compound originating from a polysaccharide-based biomass includes at least one of a saccharification step that produces a sugar solution containing a monosaccharide and/or an oligosaccharide from a product obtainable by hydrolyzing the polysaccharide-based biomass; a fermentation step that ferments the sugar solution containing the monosaccharide and/or oligosaccharide originating from the polysaccharide-based biomass; and a treatment that removes a fermentation inhibitor with the use of a separation membrane having a glucose removal rate and an isopropyl alcohol removal rate which simultaneously satisfy the following relationships (I) and (II) when a 500 ppm aqueous glucose solution at pH 6.5 at 25° C. and a 500 ppm aqueous isopropyl alcohol solution at pH 6.5 at 25° C. are respectively permeated through the membrane at an operation pressure of 0.5 MPa, prior to the saccharification step and/or in the step prior to the fermentation step: 1. A method of producing a compound originating from a polysaccharide-based biomass comprising:at least one of a saccharification step that produces a sugar solution containing 1) a monosaccharide and an oligosaccharide or 2) a monosaccharide or 3) an oligosaccharide from a product obtainable by hydrolyzing the polysaccharide-based biomass;a fermentation step that ferments the sugar solution containing 1) the monosaccharide and oligosaccharide or 2) the monosaccharide or 3) the oligosaccharide originating from the polysaccharide-based biomass; and [{'br': None, 'Glucose removal rate≧80%\u2003\u2003(I)'}, {'br': None, 'Glucose removal rate−Isopropyl alcohol removal rate≧20%\u2003\u2003(II).'}], 'a treatment step that removes a fermentation inhibitor with a separation membrane comprising at least one of cellulose acetate, polyamide, polyester, polyimide, or a vinyl polymer, having a glucose removal rate and an isopropyl alcohol removal rate which simultaneously satisfy relationships (I) and (II) when a 500 ...

Подробнее
Номер записи: 13
31-10-2013 дата публикации

GLYCOSIDE COMPOUND

Номер: US20130288992A1
Автор: AMINO YUSUKE, KUROSAWA Wataru, NOGUSA Yoshihito, Oyama Kana, TOYODA Takuya, UBAGAI Risa
Принадлежит:

Compounds of formula (I″) 10. A GLP-1 secretion promoting agent claim 1 , comprising a compound according to .11. An anorexigenic agent claim 1 , comprising a compound according to .12. A pharmaceutical composition claim 1 , comprising a compound according to and at least one pharmaceutically carrier or excipient.13. A food composition claim 1 , comprising a compound according to .14. A cosmetic composition claim 1 , comprising a compound according to .21. The method according to claim 20 , wherein said removing said hydroxyl-protecting groups is performed in the presence of a lipase.24. A method of promoting GLP-1 secretion in a mammal claim 1 , comprising administering an effective amount of a compound according to to the mammal. This application is a continuation of International Patent Application No. PCT/JP2011/079933, filed on Dec. 22, 2011, and claims priority to Japanese Patent Application No. 2010-286207, filed on Dec. 22, 2010, both of which are incorporated herein by reference in their entireties.1. Field of the InventionThe present invention relates to a particular compound. Moreover, it relates to a production method of the compound, and a glucagon-like peptide-1 (GLP-1) secretion promoting agent, a pharmaceutical composition, a food composition and a cosmetic composition, each containing the compound.2. Discussion of the BackgroundIn recent years, many studies have been made around capsaicin.JP-B-3506466 discloses capsaicin glycoside and the like. However, the capsaicin glycoside can reduce the pungent taste of capsaicin but cannot always eliminate the pungent taste completely when it is blended at a high concentration.In addition, JP-A-2007-326825 discloses a composition for controlling harmful organisms, which contains (a) 4-phenoxyphenyl (RS)-2-(2-pyridyloxy)propyl=ethyl, and (b) capsaicinoid or capsinoid, or a glycoside thereof. However, the specific saccharide residue is not shown and the use thereof is extremely limited.On the other hand, JP-B- ...

Подробнее
Номер записи: 14
07-11-2013 дата публикации

Process for producing a particulate composition comprising anhydrous crystalline 2-o-alpha-d-glucosyl-l-ascorbic acid

Номер: US20130295618A1
Автор: Seisuke Izawa, Shigeharu Fukuda, Takashi Shibuya, Tomoyuki Nishimoto, Toshio Miyake
Принадлежит: Hayashibara Co Ltd

The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside.

Подробнее
Номер записи: 15
26-12-2013 дата публикации

THERMO-PHOTO-BIOREACTOR AND METHOD FOR THE CULTURE AND MASS MICROPROPAGATION OF DESCHAMPSIA ANTARCTICA IN VITRO

Номер: US20130344528A1
Автор: Castro Oyarzún Alvaro Gonzalo, Prieto Encalada Humberto Godofredo, Sequeida Honorato Alvaro Eduardo, Tapia Rodriguez Eduardo Andres, Zamoro Cantillana Pablo Andres, Zuñiga Navarro Gustavo Emilio
Принадлежит: UNIVERSIDAD SANTIAGO DE CHILE

The invention relates to a thermo-photo-bioreactor and to a method for the culture and mass micropropagation of in vitro. The invention comprises a discontinuous immersion reactor for biomass micropropagation, including means for incorporating chemical inducing agents (salt, metals, organic compounds, etc.) and internal luminescence or illumination means (UV radiation and temperature) for supplying said chemical inducers and/or illumination during any growth phase of the vegetable or plant material (multiplication or propagation and/or maintenance). The invention is advantageous in that it can be used to produce large quantities of biomass of the aforementioned Antarctic species, while providing conditions suitable for said plant to produce metabolites that can be used for human health and personal care. 1Deschampsia antarcticaD. antarctica. A method for an in vitro culture and mass micropropagation of () , plant material , further inducing generation or biosynthesis of antioxidant and photoprotective metabolites characteristic of said plant material , such as scopoletin , chlorogenic acid , rutin , and quercetin , comprising the following steps:{'i': 'Deschampsia antarctica;', 'a) collecting parent plant material consisting of'}b) recovering said plant material from the collected parent material;c) inoculating said plant material shoots;{'i': 'D. antarctica', 'd) in vitro culturing and micropropagating said plant material by temporary immersion in MS Basal Medium (PhytoTech Lab™) that further comprises sugars, hormones, vitamins and cytokines and is at a pH between 5-6, under temperature conditions that simulate those of natural habitat;'}e) inducting the plant material of secondary compounds production by applying UV-B lighting pulses,wherein the following are used in step d): sugars selected from saccharose glucose or fructose; hormones selected from benzyl amino purine (BAP), isopentenyl adenine (2IP), indole butyric acid (IBA), GA3 or a mixture thereof; ...

Подробнее
Номер записи: 16
16-01-2014 дата публикации

Method for utilizing monoterpene glycosyltransferase

Номер: US20140020137A1
Автор: Eiichiro Ono, Nobuo Tsuruoka
Принадлежит: Suntory Holdings Ltd

The object of the present invention is to provide a novel method for producing a terpene 8-glycoside. The present invention provides a method for producing a terpene 8-glycoside by means of glycosyltransferase acting on the 8-position of terpenes. The present invention provides a transformant transformed with a gene for the glycosyltransferase acting on the 8-position of terpenes and a method for producing such a transformant. The present invention provides a plant modified to suppress the expression of a protein having glycosylation activity on the 8-position of a monoterpene compound.

Подробнее
Номер записи: 17
27-03-2014 дата публикации

Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives

Номер: US20140088030A1
Автор: Daniel Auriol, Fabrice Lefevre, Patrick Robe, Renaud Nalin
Принадлежит: Libragen SA

The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application.

Подробнее
Номер записи: 18
06-01-2022 дата публикации

HIGH-PURITY RUBUSOSIDE AND PROCESS FOR PRODUCING OF THE SAME

Номер: US20220002774A1
Автор: MARKOSYAN Avetik
Принадлежит:

The invention provides a process of producing Rubusoside from steviol glycosides of plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. 1Stevia rebaudiana. A process for preparing Rubusoside from steviol glycosides of comprising the steps of:{'i': 'Stevia rebaudiana;', 'a. providing initial steviol glycosides of'}b. dissolving the initial steviol glycosides in the water;c. providing an enzyme with glycosyl hydrolase activity to obtain reaction mixture;d. incubating the reaction mixture to facilitate complete or partial transformation of Stevioside to Rubusoside;e. terminating the reaction by thermal inactivation of enzyme;f. recovering and purifying high purity Rubusoside from reaction mixture.2Stevia. A process of wherein step (a) the steviol glycoside is extract claim 1 , mixture of steviol glycosides or pure Stevioside.3. A process of wherein step (b) the concentration of dissolved steviol glycosides is 1-50% (wt/vol) claim 1 , preferably 5-30% (wt/vol) claim 1 , more preferably 8-10% (wt/vol).4. A process of wherein step (c) the enzyme is selected from the group of rhamnosidase claim 1 , β-glucosidase claim 1 , hesperidinase claim 1 , naringinase claim 1 , pectinase claim 1 , cellulase claim 1 , and other enzymes with glycosyl hydrolase activity claim 1 , in free or immobilized forms.5. A process of wherein step (d) the molar yield of Rubusoside from Stevioside is 1-100% claim 1 , preferably 80-100% and more preferably 95-100%.6. A process of wherein step (e) the reaction termination includes heat treatment claim 1 , activated carbon treatment.7. A process of ...

Подробнее
Номер записи: 19
07-01-2016 дата публикации

IMMUNOTHERAPEUTIC POTENTIAL OF MODIFIED LIPOOLIGOSACCHARIDES/LIPID A

Номер: US20160002691A1
Автор: Ernst Robert K., Hajjar Adeline, Pelletier Mark
Принадлежит:

Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases. 1. A method of generating a lipooligosaccharide/lipid A-based mimetic , comprising the steps of: expresses one or more non-endogenous lipid A biosynthesis enzymes;', 'expresses one or more endogenous lipid biosynthesis enzymes, wherein the enzyme is modified; and/or', 'has modified regulation of one or more endogenous lipid biosynthesis enzymes; and, 'obtaining a bacterial strain that has one or more of the following modificationssubjecting the strain to conditions suitable for production of the lipooligosaccharide/lipid A composition.2. The method of claim 1 , wherein the obtaining step is further defined as engineering the bacterial strain to have one or more of the modifications.3. The method of claim 2 , wherein the engineering step comprises one or both of:delivering a vector into the bacteria; orbacterial conjugation.4. The method of claim 2 , wherein the engineering step comprises delivering a vector into the bacteria claim 2 , wherein the vector comprises sequence that encodes one or more non-endogenous lipid A biosynthesis enzymes.5. The method of claim 1 , wherein the lipooligosaccharide/lipid A-based mimetic produced by the method has a modified number of phosphates compared to the endogenous bacterial lipid A molecule or a reference lipid A molecule.6. The method of claim 1 , wherein the lipooligosaccharide/lipid A-based mimetic produced by the method has modified phosphates compared to the endogenous bacterial lipid A molecule or a reference lipid A molecule.7Yersinia pestis, Pseudomonas. The method of claim 1 , wherein the bacterial strain is claim 1 , ...

Подробнее
Номер записи: 20
12-01-2017 дата публикации

Localized Excess Protons and Methods of Making and Using Same

Номер: US20170009357A1
Автор: James Weifu Lee
Принадлежит: Individual

Localized excess protons are created with an open-circuit water electrolysis process using a pair of anode and cathode electrodes for a special excess proton production and proton-utilization system to treat a substrate material plate/film by forming and using an excess protons-substrate-hydroxyl anions capacitor-like system. The technology enables protonation and/or proton-driven oxidation of plate/film and/or membrane materials in a pure water environment. The present invention represents a remarkable clean “green chemistry” technology that does not require the use of any conventional acid chemicals including nitric and sulfuric acids for the said industrial applications. The application of localized excess protons provides a special energy recycling and renewing technology function to extract latent heat including molecular thermal motion energy at ambient temperature for generating local proton motive force (equivalent to Gibbs free energy) to do useful work such as driving ATP synthesis and proton-driven oxidation of certain substrate metal atoms.

Подробнее
Номер записи: 21
11-01-2018 дата публикации

METHOD FOR PREPARING MOGROSIDE

Номер: US20180010160A1
Автор: Ochiai Misa, Ono Eiichiro
Принадлежит: SUNTORY HOLDINGS LIMITED

The present invention provides a method for preparing a mogroside having no β-1,6-glucoside bond comprising the step of reacting glycosidase ASBGL2, AOBGL2, AOBGL1, ASBGL1, or a variant thereof with a mogroside having at least one β-1,6-glucoside bond, thereby cleaving said β-1,6-glucoside bond. 1. A method for preparing a mogroside having no β-1 ,6-glucoside bond comprising reacting a protein selected from the group consisting of proteins (a) to (c) shown below with a mogroside having at least one β-1 ,6-glucoside bond , thereby cleaving said β-1 ,6-glucoside bond:(a) a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, and SEQ ID NO: 16;(b) a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, and SEQ ID NO: 16, wherein 1 to 84 amino acids have been deleted, substituted, inserted, and/or added, and having an activity to cleave a β-1,6-glucoside bond of a mogroside; and(c) a protein having an amino acid sequence having 90% or more sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, and SEQ ID NO: 16, and having an activity to cleave a β-1,6-glucoside bond of a mogroside.2. The method according to claim 1 , wherein the protein selected from the group consisting of proteins (a) to (c) further includes a secretory signal peptide.3. The method according to claim 1 , wherein the mogroside having at least one β-1 claim 1 ,6-glucoside bond further has at least one β-1 claim 1 ,2-glucoside bond.4. The method according to claim 3 , wherein the mogroside having at least one β-1 claim 3 ,6-glucoside bond and at least one β-1 claim 3 ,2-glucoside bond is selected from mogroside V claim 3 , siamenoside I claim 3 , mogroside IV claim 3 , and mogroside IIIA.5. The method according to claim 4 , wherein the mogroside having no β-1 claim 4 ,6-glucoside bond is ...

Подробнее
Номер записи: 22
14-01-2021 дата публикации

ADENOSINE-HIGH PRODUCTION PAECILOMYCES HEPIALI CS4 STRAIN ISOLATED FROM CORDYCEPS SINENSIS

Номер: US20210010046A1
Автор: Lee Won Jae
Принадлежит:

Provided is an adenosine-high production. Cs4 strain isolated from [accession number: KCTC 13285BP]. 1Paecilomyces hepialiCordyceps sinensisCordyceps sinensis. An adenosine-high production CS4 strain isolated from [accession number: KCTC 13285BP], wherein 3 of YC1-4 strain, which is isolated from and incubated in a PDB medium for one week, is inoculated into 50 g of a pupa medium material, which is washed and sterilized with an addition of 30 of water, and a resulting product is incubated at 23° C. under a light condition for 20 days, so that a yield of adenosine is 180 mg per 100 g of the medium. The present invention relates to an adenosine-high production Cs4 strain isolated from and, more particularly, to a strain which is isolated from wild collected from Tibet region in China and has a remarkably enhanced capacity to produce adenosine.In general, some of ascomycete molds grow in insects which serve as a host. When certain conditions are met, the molds break through the insects to create fruiting bodies which are collectively called . Various have been found depending on the types of insect as a host and the types of parasitic mold fungus.As the spp. fungus, it is known that there are hundreds of species depending on strains and types of insect which serve as a host, such as with silkworm pupa as a host, , etc. Out of the species, , in which swift moth larva serves as a host, has been known to have the most excellent medical effect from a long time ago.The is collected from the high mountains of Tibet and Chinghai regions in China, Nepal and like places, and is so valuable that has been treated as one of the three traditional medicinal herbs in China.In China, however, the collection of is extremely restricted due to concerns about the destruction of natural ecology. As heavy metals such as arsenic have been recently round in natural , there concerns about the food safety of naturally collectedThe is produced in such a way that sexual and asexual spores or ...

Подробнее
Номер записи: 23
03-02-2022 дата публикации

IMPROVED PRODUCTION OF SYMMETRICAL BOLAFORM SOPHOROSIDES

Номер: US20220033869A1
Автор: Remmery Jelle, Roelants Sophie, Soetaert Wim, Van Renterghem Lisa
Принадлежит:

The present invention relates to the field of microbial production of novel biosurfactants. More specifically, the present invention discloses the usage of a fungal strain such as the yeast Starmerellabombicola having a dysfunctional CYP52M1 cytochrome P450 monooxygenase and a dysfunctional FAO1 fatty alcohol oxidase for producing high amounts of so-called “symmetrical bolaform sophorosides” where both sophorose moieties are attached through a terminal glycosidic linkage to the hydrophobic linker. In addition, the present invention further discloses that the latter yeast can also be used to produce alkyl sophorosides and symmetrical bolaform glucosides. 1StarmerellaCandidabombicola, Candida apicola, Candida batistae, Candida floricola, Candida riodocensis, Candida stellate, Candida kuoi, Candida, RhodotorulabogoriensisWickerhamiella domericqiaeStarmerella. A method to produce fully symmetrical bola sophorosides which are free from contaminating fatty acid containing sophorolipids comprising feeding a mutated fungal strain with a fatty alcohol having an aliphatic tail chain length of at least 6 carbons wherein said fungal strain has a dysfunctional CYP52M1 cytochrome P450 monooxygenase and a dysfunctional FAO1 fatty alcohol oxidase and wherein said fungal strain is a yeast selected from the group consisting of () sp. NRRL Y-27208sp. , and a sophorolipid-producing strain of the clade.2. A method according to wherein the gene encoding for the CYP52M1 cytochrome P450 monooxygenase and the gene encoding for the FAO1 fatty alcohol oxidase are knocked out.3. A method according to claim 1 , wherein said fatty alcohol having an aliphatic tail chain length of at least 6 carbons is hexanol claim 1 , octanol claim 1 , decanol claim 1 , undecyl alcohol claim 1 , lauryl alcohol claim 1 , tridecyl alcohol claim 1 , myristyl alcohol claim 1 , pentadecyl alcohol claim 1 , cetyl alcohol claim 1 , palmitoleyl alcohol claim 1 , heptadecyl alcohol claim 1 , stearyl alcohol claim 1 , ...

Подробнее
Номер записи: 24
21-01-2016 дата публикации

Methods For Selecting Microbes From A Diverse Genetically Modified Library to Detect and Optimize the Production of Metabolites

Номер: US20160017317A1
Автор: George M. Church, Jameson ROGERS, Noah D. TAYLOR, Srivatsan RAMAN
Принадлежит: Harvard College

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

Подробнее
Номер записи: 25
21-01-2021 дата публикации

METHOD FOR PREPARING SALIDROSIDE

Номер: US20210017560A1
Автор: CUI LANGJUN, GENG YINGJUN, GUI JICHENG, LIU MAODONG, MAO ZHAOLIN, ZHAO CAIHONG
Принадлежит:

The present invention provides a method for preparing salidroside. The present invention uses β-glucoside and CoFeOparticles to form a cross-linked aggregate capable of effectively catalyzing the reaction of β-D-ghucose and tyrosol, thereby increasing the yield of the salidroside. The steps of the preparation method of the present invention are simple and short, and the method is easy to operate and readily applicable to industrial production. 1. A method for preparing salidroside , comprising the following steps:{'sub': 2', '4, '(1) adding β-glucosidase into a phosphate-citric acid buffer solution, adding polyacrylamide cross-linked hollow CoFeOparticles, adding a settling agent, glutaraldehyde and sodium borohydride after oscillating, oscillating, centrifuging same at 320-480 rpm for 5-10 min, feeding same into a thermostatic water bath at 40-45° C., keeping the temperature and stirring same for 1-2 h, discharging, and collecting precipitates to obtain a β-glucosidase cross-linked aggregate;'}(2) adding β-D-glucose and tyrosol into a solvent, adding the buffer solution and the β-glucosidase cross-linked aggregate obtained in the step (1), and reacting to obtain a reaction solution; and(3) filtering the reaction solution obtained in the step (2), and carrying out reduced pressure distillation on a filtrate to obtain a crude product; and recrystallizing the crude product to obtain the salidroside.2. The method for preparing the salidroside according to claim 1 , wherein a method for preparing the polyacrylamide cross-linked hollow CoFeOparticles comprises the following steps:(1) adding 1-2 parts by weight of ammonium persulfate into deionized water which is 20-30 times of the weight of the ammonium persulfate, and uniformly stirring same; and{'sub': 2', '4, '(2) adding 40-45 parts by weight of methyl methacrylate into the deionized water which is 5-8 times of the weight of the methyl methacrylate, uniformly stirring same, feeding same into a reaction kettle, ...

Подробнее
Номер записи: 26
28-01-2016 дата публикации

Synthesis of new sialooligosaccharide derivatives

Номер: US20160024129A1
Автор: Andreas Schroven, Elise Champion, Gyula Dekany
Принадлежит: Glycom AS

The invention relates to a method for the synthesis of compounds of general formula (1A) and salts thereof wherein one of the R groups is an α-sialyl moiety and the other is H, X 1 represents a carbohydrate linker, A is a D -glucopyranosyl unit optionally substituted with fucosyl, R 1 is a protecting group that is removable by hydrogenolysis, the integer in is 0 or 1, by a transsialidation reaction.

Подробнее
Номер записи: 27
22-01-2015 дата публикации

GANGLIOSIDE COMPOSITIONS

Номер: US20150025234A1
Автор: RAGAGLIA Vanessa, Sharma Vandana Madanlal
Принадлежит:

The invention provides novel gangliosides and mixtures of novel gangliosides, and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A ganglioside characterized by a single thin layer chromatography (“TLC”) band having a retardation factor (“Rf”) value that is greater than an ovine GM1 standard Rf when said ganglioside is subjected to TLC on a glass plate coated with a 250 μm layer of ultrapure silica gel and contacted with a solution comprising chloroform , methanol and 0.2% calcium in a ratio of 50:42:11 , after which said coated glass plate is stained by being placed into a second solution comprising 80 mL of concentrated hydrochloric acid , 0.25 mL of 0.1 M cupric sulfate , 10 mL of 2% resorcinol and 10 mL of water , and said glass plate is heated in said second solution for 20 minutes at 100° C. , wherein said ganglioside comprises one or more gangliosides.2. The ganglioside of claim 1 , wherein said ganglioside is purified from a crude ganglioside mixture.3. The ganglioside of claim 2 , wherein said crude ganglioside mixture is isolated from adult human bone marrow stromal cells cultured under low oxygen.4. The ganglioside of claim 3 , wherein said low oxygen is 5% oxygen.5. The ganglioside of claim 1 , wherein said ganglioside Rf value is 0.65.6. The ganglioside of claim 1 , ...

Подробнее
Номер записи: 28
10-02-2022 дата публикации

BIOSYNTHESIS PRODUCTION OF STEVIOL GLYCOSIDES AND PROCESSES THEREFORE

Номер: US20220042060A1
Автор: Batten Michael, Byun David, Luo Yang, Mao Guohong, Vick Jacob Edward, Wu Yilin, Yu Xiaodan, Zhang Beihua
Принадлежит: Conagen Inc.

The present invention relates to the production of steviol glycoside rebaudiosides D4, WB1 and WB2 and the production of rebaudioside M from Reb D4. 154.-. (canceled)56Pichia pastoris. The reaction mixture of claim 55 , wherein the beta-glucosidase is a beta-glucosidase.57. The reaction mixture of claim 55 , wherein the beta-glucosidase comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 5.58. The reaction mixture of claim 55 , wherein the beta-glucosidase comprises the amino acid sequence of SEQ ID NO: 5.59. The reaction mixture of claim 55 , wherein the polynucleotide comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO: 6.60. The reaction mixture of claim 55 , wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 6.61. The reaction mixture of claim 55 , wherein the cell is a yeast cell.62. The reaction mixture of claim 55 , wherein the cell is a bacterial cell.63. The reaction mixture of claim 55 , wherein the cell is a plant cell.65. The reaction mixture of claim 64 , wherein the UDP glycosyltransferase comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 9.66. The reaction mixture of claim 64 , wherein the UDP glycosyltransferase comprises the amino acid sequence of SEQ ID NO: 9.67. The reaction mixture of claim 64 , wherein the polynucleotide comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO: 10.68. The reaction mixture of wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 10.69. The reaction mixture of claim 64 , wherein the cell is a yeast cell.70. The reaction mixture of claim 64 , wherein the cell is a bacterial cell.71. The reaction mixture of claim 64 , wherein the cell is a plant cell.72. The reaction mixture of claim 64 , further comprising a substrate selected from the group consisting of: sucrose claim ...

Подробнее
Номер записи: 29
23-01-2020 дата публикации

PROCESSING BIOMASS

Номер: US20200024622A1
Автор: Medoff Marshall
Принадлежит:

Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids. 1. A method of producing a polyester polymer comprising:(i) saccharifying biomass to form a saccharified biomass;(ii) contacting the saccharified biomass with a microorganism to produce one or more products; and(iii) converting the one or more products to the polyester polymer.2. The method of claim 1 , wherein the polyester polymer comprises poly(lactic acid).3. The method of claim 1 , wherein the one or more products comprises an organic acid.4. The method of claim 3 , wherein the organic acid comprises lactic acid.5. The method of claim 1 , wherein the microorganism comprises a lactic acid bacteria (LAB).6Lactobacillus.. The method of claim 1 , wherein the microorganism comprises a species in the genera7. The method of claim 1 , further comprising treating the biomass prior to step (i) to reduce its recalcitrance.8. The method of claim 7 , wherein the treating comprises size reduction (e.g. claim 7 , mechanical size reduction of individual pieces of biomass) claim 7 , radiation claim 7 , sonication claim 7 , pyrolysis claim 7 , or oxidation9. The method of claim 7 , wherein the treating comprises radiation claim 7 , e.g. claim 7 , using ionizing radiation.10. The method of claim 7 , wherein the recalcitrance of the biomass is reduced by at least about 10%.11. The method of claim 7 , wherein the recalcitrance of the biomass is reduced by 50%-90%.12. The method of claim 1 , wherein the biomass is a lignocellulosic or cellulosic material.13. The method of claim 1 , wherein the biomass comprises paper claim 1 , paper products claim 1 , paper waste claim 1 , wood claim 1 , particle board claim 1 , sawdust claim 1 , agricultural waste claim 1 , sewage claim 1 , silage claim 1 , grasses claim 1 , rice hulls claim 1 , bagasse claim 1 , cotton claim 1 , jute claim 1 , hemp claim 1 , flax claim 1 , bamboo ...

Подробнее
Номер записи: 30
23-01-2020 дата публикации

Production of Steviol Glycosides in Recombiant Hosts

Номер: US20200024630A1
Автор: Dalgaard Mikkelsen Micheael, Douchin Veronique, MØLLER-HANSEN Iben
Принадлежит:

The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors. 1. A recombinant host cell producing a steviol glycoside in a cell culture , wherein the recombinant host cell has a modified expression of an endogenous transporter gene encoding a transporter polypeptide , wherein the modified expression comprises increasing expression or activity of the endogenous transporter gene encoding the transporter polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:38 above the level of expression or activity observed in a corresponding unmodified recombinant host cell;wherein at least a portion of the steviol glycoside is transported from the recombinant host into the cell culture medium; andwherein the host cell is a plant cell, a fungal cell, or a bacterial cell.2. The recombinant host cell of claim 1 , wherein the transporter polypeptide comprises a mitochondrial protein translocase (MPT) transporter polypeptide.3. The recombinant host cell of claim 1 , further comprising:(a) one or more genes encoding a sucrose transporter (SUC1) polypeptide and a sucrose synthase (SUS1) polypeptide; 'wherein the polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:149;', '(b) a gene encoding a polypeptide capable of synthesizing geranylgeranyl pyrophosphate (GGPP) from farnesyl diphosphate (FPP) and isopentenyl diphosphate (IPP);'} 'wherein the polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:150;', '(c) a gene encoding a polypeptide capable of synthesizing ent-copalyl diphosphate from GGPP;'} 'wherein the polypeptide comprises a polypeptide having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:152;', '(d) a gene encoding a polypeptide capable of synthesizing ent-kaurene from ent-copalyl ...

Подробнее
Номер записи: 31
11-02-2016 дата публикации

KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN

Номер: US20160040206A1
Автор: Park Je Won, Park Sung Ryeol, Sohng Jae Kyung, Yoon Yeo Joon
Принадлежит:

Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved. 1. A vector comprising at least one gene set selected from the group consisting of:(1) kanA, kanB, and kanK;(2) kanA, kanB, kanK, and kanF;(3) kanA, kanB, kanK, kanF, and kacA;(4) kanA, kanB, kanK, kanF, kacA, kanC, and kanD;(5) kanA, kanB, kanK, kanF, kacA, kanI, and kacL;(6) kanA, kanB, kanK, kanF, kacA, and kanE;(7) kanA, kanB, kanK, kanF, kacA, kanE, kanC, and kanD;(8) kanA, kanB, kanK, kanF, kacA, kanE, kanI, and kacL;(9) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, and kacL;(10) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;(11) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, kacL, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;(12) kanA, kanB, kanK, and nemD;(13) kanA, kanB, kanK, nemD, kacA, kanE, kanC, and kanD;(14) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, and kacL;(15) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, kacL, aprD3, and aprD4;(16) kanA, kanB, kanK, nemD, kacA, tobM2, kanC, kanD, kanI, kacL, aprD3, and aprD4;(17) kanA, kanB, kanK, and tobM1;(18) kanA, kanB, kanK, tobM1, kacA, kanE, kanC, and kanD;(19) kanA, kanB, kanK, and gtmG; and(20) kanA, kanB, kanK, gtmG, kacA, kanE, kanC, and kanD.2Streptomyces kanamyceticusStreptomyces tenebrariusBacillus circulansStreptomyces fradiaeMicromonospora echinospora.. The vector of claim 1 , wherein the kanA claim 1 , kanB claim 1 , kanK claim 1 , kanF claim 1 , kacA claim 1 , kanE claim 1 , kanC claim 1 , kanD ...

Подробнее
Номер записи: 32
11-02-2016 дата публикации

METHOD FOR STABILISING OXIDATION-SENSITIVE METABOLITES PRODUCED BY MICROALGAE OF THE CHLORELLA GENUS

Номер: US20160040208A1
Автор: MACQUART GABRIEL
Принадлежит:

The invention relates to a method for stabilising a biomass of microalgae containing oxidation-sensitive metabolites selected from the group consisting of carotenoids (lutein, etc.), monounsaturated and polyunsaturated fatty acids (palmitoleic acid, oleic acid, linoleic acid, etc.), chlorophyll pigments (chlorophyll A and B, etc.) and vitamins (vitamin B9 and B12, etc.) taken individually or together, more specifically carotenoids, said method comprising the fermentation of said biomass in heterotrophic conditions. 113-. (canceled)14. A method for stabilizing or for storing oxidation-sensitive metabolites selected from the group consisting of the carotenoids , monounsaturated and polyunsaturated fatty acids , chlorophyll pigments , and vitamins , alone or in combination comprising:fermenting a biomass of microalgae in heterotrophic conditions comprising a culture phase deficient in a nutrient factor; andstoring the dry biomass in which the oxidation-sensitive metabolites are stabilized.15Chlorella.. The method of claim 14 , wherein the microalgae are of the genus16Chlorella sorokiniana.. The method of claim 15 , wherein the microalgae are17. The method of claim 15 , wherein the method does not comprise adding exogenous antioxidant or stabilizer to said dry biomass.18. The method of claim 15 , wherein the deficient nutrient factor is the carbon-containing source.19. The method of claim 18 , wherein the fermenting of said biomass of microalgae in heterotrophic conditions comprises:a first step of fermentation in batch mode,a second step of fermentation in fed-batch mode which, when the carbon-containing source is completely consumed by the microalgae, involves continuous supply of said carbon-containing source at a rate lower than its rate of consumption by the microalgae.20. The method of claim 18 , wherein the deficient nutrient factor is glucose and in that it is supplied to the culture at a rate above 1 g/l/h.21. The method of claim 19 , wherein the deficient ...

Подробнее
Номер записи: 33
09-02-2017 дата публикации

Algae cultivation method and production method for osmotic pressure regulator

Номер: US20170037360A1
Автор: Ayaka NAKASHIMA, Eriko YOSHIDA, Hideyuki Adachi, Keisuke Kojima, Kengo Suzuki, Masaharu TASAKI, Ryohei Nakano, Takeshi Hasegawa, Yoichi KUROIWA
Принадлежит: Euglena Co Ltd, Shimizu Corp

An algae culture method capable of efficiently producing an osmotic pressure adjusting substance, a production method of the substance, and an algae culture method for recovering carbon dioxide from a mixed gas containing carbon dioxide and sulfurous acid gas. The methods involve preparing a plurality of enrichment cultures each containing betaine by culturing a culture of microalgae derived from an environmental specimen under a photoautotrophic condition and under a plurality of culture conditions; making a cultivation plan in which an optimum enrichment culture suitable for a main culture is selected from the plurality of enrichment cultures; producing a main culture that contains betaine under the photoautotrophic condition and a salt concentration of 10 wt. % or more; and separating betaine. In the main culture, the algae containing betaine are cultured while the mixed gas containing sulfurous acid gas and carbon dioxide is blown to a culture solution of the algae.

Подробнее
Номер записи: 34
24-02-2022 дата публикации

MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES

Номер: US20220053751A1
Автор: ALIBEK Ken, DIXON Tyler, FARMER Sean, FOTSCH ALEX, MAZUMDER Sharmistha, MILOVANOVIC Maja, ZORNER Paul S.
Принадлежит:

The invention provides materials and method for controlling pests, in particular, nematodes. The invention also provides compositions comprising biosurfactants as pesticides. 1. A method for controlling nematodes wherein said method comprises contacting the nematodes with a microbe-based nematicidal composition that has been prepared by cultivating a microorganism under conditions such that the microorganism produces a biosurfactant , wherein said nematicidal composition comprises the microorganism and/or broth in which the microorganism is cultivated.2. The method claim 1 , according to claim 1 , wherein the biosurfactant is a glycolipid.3. The method claim 2 , according to claim 2 , wherein the glycolipid is a sophorolipid (SLP).4. The method claim 2 , according to claim 2 , wherein the glycolipid is a mannosylerytrithol lipid (MEL).5Starmerella, PichiaPseudozyma.. The method claim 1 , according to claim 1 , wherein the microorganism is a fungus selected from and6Starmerella bombicola.. The method claim 5 , according to claim 5 , wherein the fungus is7Pseudozyma aphidis.. The method claim 5 , according to claim 5 , wherein the fungus is8Pichia anomalaWickerhamomyces anomalus. The method claim 5 , according to claim 5 , wherein the fungus is ().9. The method claim 1 , according to claim 1 , wherein the broth is applied to nematodes claim 1 , and/or their environment claim 1 , without first separating biosurfactant from cell mass.10Meloidogyne incognitalBelonolaimus longicaudatusHeterodera glycinesPratylenchusXiphinemaTylenchulus semipenetrans. The method claim 1 , according to claim 1 , used to control a nematode selected from root-knot nematode () claim 1 , sting nematode () claim 1 , soybean cyst nematode () claim 1 , lesion nematode (sp.) claim 1 , dagger nematode (sp.) claim 1 , and citrus nematode ().11. The method claim 1 , according to claim 1 , wherein said method is used to control nematode pests of plants.12. The method claim 11 , according to claim 11 , ...

Подробнее
Номер записи: 35
08-02-2018 дата публикации

METHOD FOR THE REGIOSELECTIVE DEACETYLATION OF MANNOSYLERYTHRITOL LIPIDS

Номер: US20180037916A1
Автор: Goossens Eliane Yvonne, Wijnants Marc Victor Henri
Принадлежит: UNIVERSITEIT ANTWERPEN

The present invention relates to methods for the enzymatic deacetylation of mannosylerythritol lipids produced by fermentation using lipases. More in particular, the present invention relates to a method for the enzymatic deacetylation of mannosylerythritol lipids using a hydrolyzing enzyme in an organic solvent containing only low amounts of water, preferably, no water. It further provides the use of organic solvents, containing only low amounts of water, more preferably, no water, for the enzymatic deacetylation of mannosylerythritol lipids. 6. The method according to ; wherein the C2-C8 alcohol is selected from the group consisting of linear and branched C2-C8 alcohols.7. The method according to claim 1 , wherein the organic solvent contains less than 9% water.8. The method according to claim 1 , wherein the organic solvent contains no additional water.9. The method according to claim 1 , wherein the hydrolyzing enzyme is a lipase.10. (canceled)11. The method according to ; wherein the C2-C8 alcohol is selected from the group consisting of ethanol claim 1 , 1-propanol claim 1 , 1-butanol claim 1 , 1-pentanol claim 1 , 1-hexanol claim 1 , 1-heptanol claim 1 , 1-octanol claim 1 , isopropanol claim 1 , isobutanol claim 1 , t-butanol claim 1 , 2-pentanol claim 1 , isoamyl alcohol claim 1 , 2-ethylhexanol claim 1 , cyclohexanol claim 1 , and benzylalchohol.12. The method according to claim 1 , wherein the organic solvent contains less than 3% water.1314.-. (canceled)15Candida antarctica. The method as defined in claim 9 , wherein the lipase is a lipase B. The present invention relates to methods for the enzymatic deacetylation of mannosylerythritol lipids produced by fermentation. More in particular, the present invention relates to a method for the enzymatic deacetylation of mannosylerythritol lipids using a lipase in an organic solvent containing only low amounts of water, preferably, no water. It further provides the use of organic solvents, containing only low ...

Подробнее
Номер записи: 36
07-02-2019 дата публикации

ENHANCED PRODUCTION OF RHAMNOLIPIDS USING AT LEAST TWO CARBON SOURCES

Номер: US20190040433A1
Автор: Lohitharn Nattaporn
Принадлежит: Logos Technologies LLC

Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source. 1. A semi-continuous method for producing a plurality of fermentations comprising one or more rhamnolipids (RL) comprising:(a) culturing a rhamnolipid producing microorganism in culture medium comprising at least two carbon sources, wherein at least one carbon source is a sweetener and at least one carbon source is an oil containing medium or long chain triglycerides, at least one nitrogen source, at least one phosphorous source, at least one magnesium source, at least one potassium source, at least one sulfur source, at least one chloride source, and at least one sodium source and optionally in the presence of an emulsifier for at least about 1 day to obtain a first fermentation medium comprising rhamnolipid comprising one or more rhamnolipids (RL) and at least one rhamnolipid producing microorganism;(b) removing at least about 70% of said first fermentation medium obtained in step (a);(c) replacing said first fermentation medium removed in (b) with culture medium having the composition set forth in step (a);(d) repeating steps (a)-(c) at least one time to obtain a subsequent fermentation medium comprising rhamnolipids and at least one rhamnolipid producing microorganisms.2. The method according to claim 1 , wherein said method yields RL at a rateof at least about 1.7 g RL/L/h.3. The method according to claim 1 , wherein said method yields at least about 40 g RL/L.4. The method according to claim 1 , wherein said rhamnolipid producing microorganism is cultured in step (a) for about 1 to about 4 days.5. The method according to claim 1 , which further comprises adding a composition comprising one or more micronutrients at a concentration of no more than 20 mg/L of micronutrient solution to said culture medium in step (a) at 0.1% v/v of total fermentation volume per day.6. The method according to claim 1 ...

Подробнее
Номер записи: 37
06-02-2020 дата публикации

CYCLIC DINUCLEOTIDES CONTAINING BENZIMIDAZOLE, METHOD FOR THE PRODUCTION OF SAME, AND USE OF SAME TO ACTIVATE STIMULATOR OF INTERFERON GENES (STING)-DEPENDENT SIGNALING PATHWAYS

Номер: US20200040028A1
Автор: Genieser Hans-Gottfried, RENTSCH Andreas, SCHWEDE Frank
Принадлежит:

Cyclic dinucleotides are described, which in contrast to their natural congeners carry lipophilic nucleobases and have higher membrane permeability and increased biological activity. 3. The compound according to claim 1 , wherein Rand/or Ris SH; or Rand/or Ris BH; or Ris SH and Ris BH; or Ris BHand Ris SH.4. The compound according to claim 1 , wherein the connections via O* and O** are realized by Rand Rleading to compounds usually assigned as 3′ claim 1 , 5′-3′ claim 1 , 5′-connected.5. The compound according to claim 1 , wherein the connections via O* and O** are realized by Rand Rleading to compounds commonly assigned as 2′ claim 1 , 5′-3′ claim 1 , 5′-connected.6. The compound according to claim 1 , wherein Rand Reach are Cl; or each R claim 1 , Rand Rare Cl; or Ris CFand Rand Reach are Cl.7. The compound according to claim 1 , wherein Ror Rand Ror Reach are OH; or Ror Ris F and Ror Ris OH; or Ror Ris OH and Ror Ris F; or Ror Rand Ror Reach are F.8. The compound according to claim 1 , wherein the structure in accordance with Formula (I) is chosen from:(1) cyclic (benzimidazole riboside-(3′->5′)-monophosphate-benzimidazole riboside-(3′->5′)-monophosphate);(2) cyclic (benzimidazole riboside-(2′->5′)-monophosphate-benzimidazole riboside-(3′->5′)-monophosphate);(3) cyclic (benzimidazole riboside-(2′->5′)-monophosphate-benzimidazole riboside-(2′->5′)-monophosphate);(4) cyclic (benzimidazole riboside-(3′->5′)-monophosphorothioate-benzimidazole riboside-(3′->5′)-monophosphorothioate);(5) cyclic (benzimidazole riboside-(2′->5′)-monophosphorothioate-benzimidazole riboside-(3′->5′)-monophosphorothioate);(6) cyclic (benzimidazole riboside-(2′->5′)-monophosphorothioate-benzimidazole riboside-(2′->5′)-monophosphorothioate);(7) cyclic (5,6-dichlorobenzimidazole riboside-(3′->5′)-monophosphate-5,6-dichlorobenzimi-dazole riboside-(3′->5′)-monophosphate);(8) cyclic (5,6-dichlorobenzimidazole riboside-(2′->5′)-monophosphate-5,6-dichlorobenzimi-dazole riboside-(3′->5′)- ...

Подробнее
Номер записи: 38
16-02-2017 дата публикации

METHOD FOR THE SYNTHESIS OF CLOFARABINE

Номер: US20170044204A1
Автор: Matvienko Victor, Matviienko Iaroslav, Sypchenko Volodymyr, Zabudkin Alexander
Принадлежит:

The present invention relates to a method for the high yield production of the anticancer nucleoside clofarabine, the method comprising the preparation of 2-chloroadenosine by enzymatic transglycosylation between 2-chloroadenine and nucleosides, benzoylation, isomerization, sulfonate ester formation, fluorination, and deprotection. 2. The method of claim 1 , wherein the transglycosylation in step (a) is performed by using purine nucleoside phosphorylase or a combination of purine nucleoside phosphorylase and uridine phosphorylase.3. The method of claim 1 , wherein the fluorination in step (e) is performed by using a fluorinating agent.4. The method of claim 3 , wherein the fluorinating agent is selected from the group consisting of hydrofluoric acid and a mixture of hydrofluoric acid and an organic Lewis base.5. The method of claim 4 , wherein the organic Lewis base is an amine.6. The method of claim 1 , wherein Ris a pyrimidine base representing uridine.7. The method of claim 1 , wherein Ris a hydroxyl protecting group representing benzoyl.8. The method of claim 1 , wherein ORis a leaving group representing trifluoromethanesulfonate. The present invention is directed to a method for the production of clofarabine in high yield and without formation of undesired α-N9 stereoisomers.Clofarabine (systematic IUPAC name: 5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxyl-methyl)oxolan-3-ol) is a purine nucleotide antimetabolite used for the treatment of various types of leukemias, in particular acute lymphoblastic leukemia.Several methods for the production of clofarabine are currently established in the art. The synthesis routes are typically based on a coupling reaction between the purine derivatives and an arabinofuranosyl fragment. Depending on the method of fluorine atom introduction, these synthesis schemes can be divided into two groups: (i) methods in which a fluorine atom is included in a ribofuranose fragment and introduced in the molecule at the coupling step ...

Подробнее
Номер записи: 39
16-02-2017 дата публикации

Methods for Recombinant Production of Saffron Compounds

Номер: US20170044552A1
Автор: Kumar A.S. Sathish
Принадлежит:

Recombinant microorganisms and methods for producing saffron compounds including hydroxy-β-cylcocitral and picrocrocin are disclosed herein. Methods involve expression of a gene encoding a cytochrome p450 polypeptide, and optionally a gene encoding a (2Fe-2S) ferredoxin polypeptide, a gene encoding a flavin-dependent ferredoxin reductase, and a gene encoding a uridine 5′-diphospho glycosyltransferase (UGT) polypeptide. 1. A recombinant host that expresses a gene encoding a cytochrome p450 polypeptide , a gene encoding a (2Fe-2S) ferredoxin polypeptide , and a gene encoding a flavin-dependent ferredoxin reductase , wherein at least one of said genes is a recombinant gene.2. The recombinant host of claim 1 , wherein the cytochrome p450 polypeptide comprises a cytochrome p450 polypeptide having 40% or greater identity to the amino acid sequence set forth in SEQ ID NO:2.3. The recombinant host of claim 1 , wherein the (2Fe-2S) ferredoxin polypeptide comprises a (2Fe-2S) ferredoxin polypeptide having 40% or greater identity to the amino acid sequence set forth in SEQ ID NO:4.4. The recombinant host of claim 1 , wherein the flavin-dependent ferredoxin reductase polypeptide comprises a flavin-dependent ferredoxin reductase polypeptide having 40% or greater identity to the amino acid sequence set forth in SEQ ID NO:6.5. The recombinant host of claim 1 , wherein the cell further expresses a gene encoding a uridine 5′-diphospho glycosyltransferase (UGT) polypeptide.6. The recombinant host of claim 5 , wherein the gene is set forth in SEQ ID NO:7.7. The host of claim 5 , wherein the UGT polypeptide comprises a polypeptide having 40% or greater identity to the amino acid sequence set forth in SEQ ID NO:8.8. The recombinant host of any one of - claim 5 , herein the recombinant host comprises a yeast cell claim 5 , a plant cell claim 5 , a mammalian cell claim 5 , an insect cell claim 5 , a fungal cell claim 5 , a bacterial cell claim 5 , an algal cell claim 5 , or a ...

Подробнее
Номер записи: 40
16-02-2017 дата публикации

SOPHOROLIPID-CONTAINING COMPOSITIONS

Номер: US20170044586A1
Автор: DURAN Anthony Louis
Принадлежит:

A process to produce a sophorolipid composition is disclosed, the steps including obtaining a sophorolipid containing composition having a pH of less than 5, adding 6 percent by weight or less of a free fatty acid to the composition, and thereafter adjusting the pH of the composition to a pH greater than 5. In some embodiments, the sophorolipid composition initially comprises from 4 to 80 percent by weight dry solids. 1. A process to produce a sophorolipid composition , the process comprising:(a) obtaining a sophorolipid containing composition comprising about 4-80 percent by weight total dry solids, comprising at least one sophorolipid, wherein the sophorolipid containing solution exhibits a pH of less than 5,(b) adding about 6 percent by weight or less of a least one free fatty acid to the sophorolipid containing composition to provide a fatty acid adjusted sophorolipid composition, and(c) adjusting the pH of the fatty acid adjusted sophorolipid composition to a pH greater than 5 to provide the sophorolipid composition.2. The process of claim 1 , wherein the total dry solids of (a) comprises from about 40 to about 99 percent by weight total sophorolipids based on the total dry solids.39-. (canceled)10. The process of claim 13 , wherein the sophorolipid containing composition of (a) comprises less than 75 percent by weight water.1112-. (canceled)13. The process of claim 1 , wherein the sophorolipid containing composition of (a) comprises 25-96 percent by weight water.13. (canceled)14. The process of claim 1 , wherein separating the sophorolipid layer from an aqueous layer comprises heating a fermentation broth containing sophorolipid to a temperature of about 70-75° C. to provide a heated broth claim 1 , cooling the heated broth to an ambient temperature claim 1 , and decanting a higher density sophorolipid layer from a lower density aqueous layer.15. The process of claim 1 , wherein the at least one sophorolipid comprises ester-form sophorolipid and acidic-form ...

Подробнее
Номер записи: 41
15-02-2018 дата публикации

Immobilized Reaction Device and a Method for Carrying out a Reaction by Utilizing the Immobilization Technology

Номер: US20180044622A1
Автор: Chen Junming, Poon Wing Keung Eric, SHEN Dong, Siu Yau Lung, Sun Liang, Wang Jun
Принадлежит:

The present invention provides an immobilized reaction device and a method for carrying out reaction by utilizing the immobilization technology. The immobilized reaction device includes a columnar reactor with an inlet and an outlet. The reactor is provided with an interior cavity which is defined by a top portion and a bottom portion opposite to each other, and a side wall connecting the top portion and the bottom portion. 1. An immobilized reaction device comprises a columnar reactor with an inlet and an outlet , wherein the columnar reactor has an interior cavity which is defined by a top portion , a bottom portion and a side wall that connects the top portion and the bottom portion , wherein a carrier immobilized with enzyme or cells is filled within the interior cavity of the columnar reactor to form a column body , and the column body has a side surface opposite to the side wall of the reactor and there is essentially no gap between the side surface of the column body and the side wall of the reactor.2. The immobilized reaction device according to claim 1 , wherein the reactor allows reaction fluid to pass through the reactor at a flow rate up to 100 V/min claim 1 , while the fluid pressure difference between the inlet and the outlet of the reactor maintains at equal or less than 0.3 MPa claim 1 , wherein V represents the volume of the interior cavity of the reactor.3. The immobilized reaction device according to claim 1 , wherein the ratio of the height of the column body to the height of the interior cavity is (0.3-1.0):1.4. The immobilized reaction device according to claim 1 , wherein the carrier is a porous organic foam material with open pores claim 1 , and the shape of the carrier includes granular claim 1 , block claim 1 , columnar shape claim 1 , sheet or strip.5. The immobilized reaction device according to claim 1 , or wherein the carrier has a natural water wetting rate of at least 0.2 mm/s.6. The immobilized reaction device according to claim 1 , ...

Подробнее
Номер записи: 42
03-03-2022 дата публикации

AMPHOTERIC GLYCOLIPID BIOSURFACTANT AND ITS PREPARATION METHOD

Номер: US20220064689A1
Автор: Xia Wenjie
Принадлежит: Mikros Biochem

Provided herein are amphoteric glycolipid biosurfactants containing an amphoteric glycolipid biological surface active molecule preparation produced by acid precipitation of culture supernatant produced by sequentially culturing , and , for instance in a fermentation medium comprising a hydrophilic carbon source and a hydrophobic carbon source. Also described are amphoteric glycolipid biological surface active molecule preparations, and methods of making such preparations. The amphoteric molecules have anionic and cationic groups; example molecules include 17-L-[(2′-O-β-D-glucopyranosyl-β-D-Glucosyl)-O-]-octadecenoic acid amine-6′,6″ diacetate, and 17-L-[(2′-O-β-D-glucopyranosamine-β-D-rhamnosyl)-O-]-octadecenoic acid-6′,6″ diacetate. The amphoteric glycolipid biosurfactant has good compatibility with other types of surfactants, high temperature resistance and salt resistance, and is suitable for use in a variety of liquid systems. 2. The amphoteric glycolipid biosurfactant of claim 1 , comprising:0.5-3.0% fatty acids,0.1-1.0% polysaccharide,20.0-40.0% amphoteric glycolipid biological surface active molecule preparation,0.1%-0.5% glycosamine,0.01-0.2% lipopeptide,1-3% ethanol, and0.1-0.5% fatty amine.3. The amphoteric glycolipid biosurfactant of claim 1 , wherein the polysaccharide:comprises a polysaccharide polymer comprising one or more of rhamnose, mannose, or glucose; andhas a molecular weight greater than 200,000 Daltons.4. The amphoteric glycolipid biosurfactant of claim 1 , wherein the fatty acid comprises a C-Clong-chain fatty acid.5. The amphoteric glycolipid biosurfactant of claim 1 , wherein the sugar amine comprises N-acetylglycosamine of glucose with a molecular weight of less than 1000 Daltons.6. The amphoteric glycolipid biosurfactant of claim 1 , wherein the lipopeptides comprise at least one lipopeptide containing 7-14 amino acid chains claim 1 , with a molecular weight of 800-3000 Daltons.7. The amphoteric glycolipid biosurfactant of claim 6 , ...

Подробнее
Номер записи: 43
08-05-2014 дата публикации

FAGOPYRITOL SYNTHASE GENES AND USES THEREOF

Номер: US20140127750A1
Автор: OBENDORF Ralph L., UEDA Takashi
Принадлежит: CORNELL UNIVERSITY

The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor. 1. An isolated nucleic acid molecule encoding a fagopyritol synthase , wherein the nucleic acid moleculeis at least 80% identical to SEQ ID NO:5 by basic BLAST using default parameters analysis.2Fagopyrum esculentum.. The isolated nucleic acid molecule according to claim 1 , wherein the fagopyritol synthase is from3. The isolated nucleic acid molecule according to claim 2 , wherein the nucleic acid molecule has a nucleotide sequence of SEQ ID NO:5.4. The isolated nucleic acid molecule according to claim 2 , wherein the nucleic acid molecule encodes a protein or polypeptide comprising an amino acid sequence of SEQ ID NO:6.5. The isolated nucleic acid molecule according to claim 1 , wherein the encoded fagopyritol synthase retains biological activity similar to a fagopyritol synthase encoded by SEQ ID NO:5.6Fagopyrum esculentum. An isolated nucleic acid molecule encoding a fagopyritol synthase from claim 1 , wherein the nucleic acid molecule(i) is at least 55% identical to SEQ ID NO:5 by basic BLAST using default parameters analysis and or(ii) hybridizes to a complement of the nucleotide sequence of SEQ ID NO:5 under stringent conditions characterized by a hybridization buffer comprising 5×SSC at a temperature of 55° C.7. An expression vector comprising transcriptional and translational regulatory nucleotide sequences operably linked to the nucleic acid ...

Подробнее
Номер записи: 44
13-02-2020 дата публикации

PROCESS FOR PRODUCTION OF A SOLID MATERIAL CONTAINING ISOMALTULOSE CRYSTALS AND TREHALULOSE

Номер: US20200048672A1
Автор: Hellmers Frank, OEHRLEIN Johannes, SCHLEGEL-KACHEL Sibylle, WOLTER Jan
Принадлежит: EVONIK DEGUSSA GmbH

The present invention provides a process for production of a solid material containing isomaltulose crystals and trehalulose comprising the process steps A) bringing an enzyme complex which is able to catalyse the reaction of sucrose to isomaltulose and trehalulose into contact with a sucrose-containing solution; B) isomerizing at least some of the sucrose to isomaltulose and trehalulose; C) separating off the enzyme complex to give a solution containing isomaltulose, trehalulose and water; D) partial removal of the water by evaporation, while obtaining a concentrated solution with, based on the total solution, a solid content of 75 wt % to 95 wt %, preferably 80 wt % to 93 wt %, particularly preferably 86 wt % to 92 wt %; E) bringing the concentrated solution to a temperature of 30° C. to 63° C., preferably 45° C. to 62° C., even more preferably 55° C. to 60° C., and subsequent induction of isomaltulose crystallisation in this temperature range followed by cooling while obtaining a solid material containing isomaltulose crystals and trehalulose. 1. A process for production of a solid material comprising isomaltulose crystals and trehalulose , the process comprising:A) bringing an enzyme complex which is able to catalyse a reaction of sucrose to isomaltulose and trehalulose into contact with a sucrose-comprising solution;B) isomerizing at least some of the sucrose in the sucrose-comprising solution to isomaltulose and trehalulose;C) separating off the enzyme complex, to obtain a solution comprising isomaltulose, trehalulose and water;D) partially removing the water by evaporation, to obtain a concentrated solution with a solid content of 75 wt % to 95 wt %, based on a total weight of the concentrated solution;E) bringing the concentrated solution to a temperature of 30° C. to 63° C., and subsequent induction of isomaltulose crystallization in this temperature range followed by cooling, to obtain a solid material comprising isomaltulose crystals and trehalulose.2. ...

Подробнее
Номер записи: 45
13-02-2020 дата публикации

PRODUCTION OF FERMENTATION PRODUCTS CONTAINING RHAMNOLIPIDS

Номер: US20200048673A1
Автор: Invally Krutika, Ju Lu-Kwang
Принадлежит:

In various aspects, the present invention is directed to a scalable method of producing rhamnolipids by bacterial fermentation with higher product concentrations, yields and productivities and preventing excessive foaming during the cell growth phase when the cell respiration rate is higher. It has been found that by slowing the growth rate of the bacteria by altering the ratio of the nitrogen source to the non-nitrogen source in the initial fermentation medium and supplementing the nitrogen source, excessive foaming in the growth phase can be prevented. Further, by using the non-nitrogen source as the limiting nutrient that initiates the stationary phase and then supplementing fermentation broth with the nitrogen and carbon sources, the length of the standing phase, and with it the time during which rhamnolipid production occurs can be greatly extended. 1. A method for improving production rates , conversions and concentrations of rhamnolipids during fermentation-based rhamnolipid production comprising:A) growing a rhamnolipid producing bacteria in a fermentation broth comprising at least one carbon source, at least one nitrogen source and a non-nitrogen source; andB) after the growth of said rhamnolipid producing bacteria is substantially complete, adding one or more additional quantities of a nitrogen source to the fermentation broth to maintain a substantially non-decreasing rate of rhamnolipids production.2Pseudomonas aeruginosa.. The method of wherein the rhamnolipid producing bacteria is3. The method of wherein the step of growing (step A) further comprises:1) determining a quantity of each one of said at least one carbon source, at least one nitrogen source, and non-nitrogen source necessary to grow said rhamnolipid producing bacteria to a desired cell concentration;2) forming an initial fermentation medium comprising some or all of said quantity of the at least one carbon source necessary to grow said rhamnolipid producing bacteria to the desired cell ...

Подробнее
Номер записи: 46
26-02-2015 дата публикации

CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS

Номер: US20150056658A1
Автор: Schaffer Steffen, Thiessenhusen Anja, Wessel Mirja
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids. 1. (canceled)2. An isolated or purified sophorolipid-producing cell transformed with a nucleic acid encoding:{'sub': '1', '(a) an Epolypeptide comprising SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63; or'}(b) a polypeptide which catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid, wherein said polypeptide comprises a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion;{'sub': 2', '3', '4', '5', '3', '4, 'wherein said cell may optionally contain a nucleic acid encoding at least one E, E, Eor Epolypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an Eand/or Epolypeptide;'}wherein{'sub': 2', '2, 'Ecomprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 8 or 11 have been modified by deletion, substitution, and/or insertion, wherein the Epolypeptide catalyzes the conversion of UDP-glucose and 17-hydroxy-Z-9-octadecenoic acid into 17-(β-D-glucopyranosyloxy)-Z-9-octadecenoic acid;'}{'sub': 3', '3, 'Ecomprises (a) the amino acid sequence selected of SEQ ID NO: 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 11 which is identical to the amino acid sequence of SEQ ID NO: 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 11 have been modified by deletion, substitution, and/or insertion, ...

Подробнее
Номер записи: 47
26-02-2015 дата публикации

CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS

Номер: US20150056659A1
Автор: Schaffer Steffen, Thiessenhusen Anja, Wessel Mirja
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids. 1. (canceled)2. An isolated or purified sophorolipid-producing cell:(i) transformed with a nucleic acid encoding an E3 polypeptide; or{'sub': '3', '(ii) modified to disrupt at least one endogenous gene encoding an Epolypeptide;'}{'sub': '3', 'wherein said E3 polypeptide comprises (a) an Epolypeptide of SEQ ID NO: 11; or (b) an E3 polypeptide that catalyzes the conversion of 17-(β-D-glucopyranosyloxy)-Z-9-octadecenoic acid and UDP-glucose into 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid, wherein said polypeptide comprises a variant of the amino acid sequence of SEQ ID NO: 11 which is identical to SEQ ID NO: 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 11 have been modified by deletion, substitution, and/or insertion;'}{'sub': 1', '2', '4', '5', '3', '4, 'wherein said cell may optionally contain a nucleic acid encoding at least one E, E, Eor Epolypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an Eand/or Epolypeptide; wherein{'sub': '1', 'Ecomprises (a) a polypeptide of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion; and catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid;'}{'sub': 2', '2, 'Ecomprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one ...

Подробнее
Номер записи: 48
26-02-2015 дата публикации

Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids

Номер: US20150056660A1
Автор: Anja Thiessenhusen, Mirja Wessel, Steffen Schaffer
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.

Подробнее
Номер записи: 49
26-02-2015 дата публикации

CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS

Номер: US20150056661A1
Автор: Schaffer Steffen, Thiessenhusen Anja, Wessel Mirja
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids. 1. (canceled)2. An isolated or purified sophorolipid-producing cell: [{'sub': 5', '5, 'wherein Ecomprises (a) the amino acid sequence of SEQ ID NO: 10; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 10 which is identical to the amino acid sequence of SEQ ID NO: 10 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 10 have been modified by deletion, substitution, and/or insertion, wherein the Epolypeptide has the ability to transfer a sophorolipid out of the sophorolipid-producing cell into the surrounding medium;'}, {'sub': 1', '2', '3', '4', '3', '4, 'wherein said cell may optionally contain a nucleic acid encoding at least one E, E, Eor Epolypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an Eand/or Epolypeptide; wherein, {'sub': '1', 'Ecomprises (a) a polypeptide of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion; and catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid;'}, {'sub': 2', '2, 'Ecomprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or 11; or (b) comprises a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 8 or 11 have been modified by deletion, substitution, and/or insertion, wherein the Epolypeptide catalyzes the conversion of UDP-glucose and 17-hydroxy-Z-9-octadecenoic ...

Подробнее
Номер записи: 50
26-02-2015 дата публикации

Compositions and Methods for the Inhibition of Methyltransferases

Номер: US20150057243A1
Автор: Bai Tianyi, Qu Wanlu, Zhou Zhaohui Sunny
Принадлежит: Northern University

Methods and compositions disclosed herein relate to detecting, analyzing, isolating and inhibiting methyltransferases, methyltransferase substrates, S-adenosyl-methionine-binding proteins and RNA, including for the treatment of disease. 2. The compound of claim 1 , wherein Ris selected from the group consisting of adenosine claim 1 , deoxyadenosine claim 1 , guanosine claim 1 , deoxyguanosine claim 1 , 5-methyluridine claim 1 , thymidine claim 1 , uridine claim 1 , deoxyuridine claim 1 , cytidine claim 1 , deoxycytidine claim 1 , formycin claim 1 , aristeromycin claim 1 , didanosine claim 1 , inosine claim 1 , acyclovir claim 1 , deoxyinosine claim 1 , abacavir claim 1 , N4-acetylcytidine claim 1 , allopurinol riboside claim 1 , 2′-O-allyladenosine claim 1 , 3′-O-allyladenosine claim 1 , 3′-O-allylcytidine claim 1 , 2′-O-allylcytidine claim 1 , 2′-O-allylguanosine claim 1 , 3′-O-allylguanosine claim 1 , 2′-O-allyluridine claim 1 , 3′-O-allyluridine claim 1 , bromodeoxyuridine claim 1 , cytarabine claim 1 , azacitidine claim 1 , decitabine claim 1 , pseudouridine claim 1 , S-adenosyl-L-homocysteine claim 1 , pentostatin claim 1 , regadenoson claim 1 , telbivudine claim 1 , 8-oxo-2′-deoxyguanosine claim 1 , CGS-21680 claim 1 , floxuridine claim 1 , 5-methyluridine claim 1 , dihydrouridine claim 1 , nelarabine claim 1 , xanthosine claim 1 , maribavir claim 1 , 8-hydroxyguanosine claim 1 , N4-chloroacetylcytosine arabinoside claim 1 , sapacitabine claim 1 , orotidine claim 1 , queuosine claim 1 , lysidine claim 1 , fialuridine claim 1 , CP-532 claim 1 ,903 claim 1 , cordycepin claim 1 , tezacitabine claim 1 , dexelvucitabine claim 1 , N6-cyclopentyladenosine claim 1 , iododeoxyuridine claim 1 , PSI-6130 claim 1 , 5 claim 1 ,6-dichloro-1-beta-D-ribofuranosylbenzimidazole claim 1 , S-adenosylmethioninamine claim 1 , FV-100 and 5-ethynyl-2′-deoxyuridine claim 1 , 9-β-D-allopyranosyl-9H-Purin-6-amine claim 1 , (S)-9-(2 claim 1 ,3-dihydroxypropyl)adenine (DHPA) claim 1 , D- ...

Подробнее
Номер записи: 51
10-03-2022 дата публикации

METHODS OF GANGLIOSIDE PRODUCTION

Номер: US20220073959A1
Автор: RAGAGLIA Vanessa, Sharma Vandana Madanlal
Принадлежит:

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g. GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO) cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. The method of claim 5 , wherein said fibroblast cell is a fibroblast from a human with GM1 gangliosidosis.8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

Подробнее
Номер записи: 52
28-02-2019 дата публикации

Sophorolipid Highly-Productive Mutant Strain

Номер: US20190062723A1
Автор: HAYASE Atsuko, ICHIHARA Takahiro, TAKAHASHI Fumikazu, TOHATA Masatoshi
Принадлежит: KAO CORPORATION

Provided is a microorganism exhibiting high production capability for sophorolipids. Disclosed is a yeast mutant strain having high sophorolipid productivity, in which a transporter transporting Acyl-CoA to a peroxisome has been deleted or deactivated. 1. A sophorolipid-producing yeast mutant strain , in which a transporter transporting Acyl-CoA to a peroxisome has been deleted or deactivated.2. The mutant strain according to claim 1 , wherein the transporter transporting Acyl-CoA to a peroxisome is PXA1 claim 1 , PXA2 claim 1 , or a protein equivalent thereto.3. The mutant strain according to claim 2 , whereinthe PXA1 is a protein consisting of the amino acid sequence set forth in SEQ ID NO:2,the PXA2 is a protein consisting of the amino acid sequence set forth in SEQ ID NO:4,the protein equivalent to PXA1 is a protein consisting of an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:2, and forming a heterodimer together with PXA2 or a protein equivalent thereto to work as a transporter transporting Acyl-CoA to a peroxisome, andthe protein equivalent to PXA2 is a protein consisting of an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:4, and forming a heterodimer together with PXA1 or a protein equivalent thereto to work as a transporter transporting Acyl-CoA to a peroxisome.4. The mutant strain according to claim 2 , wherein PXA1 gene claim 2 , PXA2 gene claim 2 , or a gene equivalent thereto has been deleted or deactivated.5. The mutant strain according to claim 4 , whereinthe PXA1 gene is a gene encoding a protein consisting of the amino acid sequence set forth in SEQ ID NO:2,the PXA2 gene is a gene encoding a protein consisting of the amino acid sequence set forth in SEQ ID NO:4,the gene equivalent to PXA1 gene is a gene encoding a protein that forms a heterodimer together with PXA2 or a protein equivalent thereto to work as a transporter transporting Acyl- ...

Подробнее
Номер записи: 53
28-02-2019 дата публикации

IDENTIFICATION AND CHARACTERIZATION OF UDP-GLUCOSE:PHLORETIN 4'-O-GLUCOSYLTRANSFERASE FROM MALUS X DOMESTICA BORKH

Номер: US20190062768A1
Автор: IBDAH Mwafaq
Принадлежит: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organizat

A method of producing trilobatin is disclosed. The method comprising contacting a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity with phloretin and UDP-glucose under conditions which allow the formation of trilobatin, thereby producing trilobatin. A method of producing a plant which produces trilobatin, transgenic plant or plant cell and methods of producing transgenic plants are disclosed. Composition comprising trilobatin are also disclosed. 1. A method of producing trilobatin , the method comprising contacting a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity with phloretin and UDP-glucose under conditions which allow the formation of trilobatin , thereby producing trilobatin.2. The method of claim 1 , being effected in vivo.3. The method of claim 2 , wherein said in vivo is in a plant cell.47-. (canceled)8. The method of claim 1 , further comprising purifying said trilobatin.9. A method of producing a plant which produces trilobatin claim 1 , the method comprising upregulating in the plant expression of a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity claim 1 , and wherein said plant comprises phloretin and UDP-glucose claim 1 , thereby producing the plant.10. The method of claim 9 , wherein said upregulating comprises genetic engineering.11. (canceled)12. A transgenic plant or plant cell comprising an exogenous nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 8 and having a 4′-O-glycosyltransferase activity.13. A method of producing the transgenic plant of claim 12 , the method comprising introducing into a cell of the plant a nucleic acid construct comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at ...

Подробнее
Номер записи: 54
08-03-2018 дата публикации

TRANS-RESVERATROL POLYSACCHARIDE, METHOD OF PRODUCING THE SAME, AND COMPOSITION COMPRISING THE SAME

Номер: US20180066005A1
Автор: HAMADA HIROKI, Kojima Shinichi, MOMOTA CHIEMI, TAKAHASHI SHOJI
Принадлежит:

An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. Another object of the present invention is to provide a trans-resveratrol derivative that has no toxicity against cells and has sufficient antioxidative properties and/or a sufficient whitening effect. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin glucanotransferase. 113-. (canceled)16. The method of wherein the skin is the skin of the scalp.17. The method of wherein the skin is the skin of the scalp.18. The method of wherein the compound of formula (7) and the compound of formula (1) are formulated in a single composition.19. The method of wherein the compound of formula (7) and the compound of formula (1) are formulated in separate compositions. The present invention relates to trans-resveratrol polysaccharide, a method for producing the same, a liposome comprising the same, and a composition comprising the same.It is widely known that resveratrol exhibits antioxidative properties, such as protection from cell death induced by hydrogen peroxide, etc., in the body. However, resveratrol is poorly soluble in water, and monosaccharide glycosides of resveratrol, which have improved water solubility, are known.Further, as shown in PTL 1, a technique using cyclodextrin glucanotransferase has been developed as a technique for producing polysaccharides of polyphenols.Moreover, it has been revealed that trans-resveratrol has the effects of inducing NFκB activation, etc., but cis-resveratrol does not have such effects (NPL 1).The present inventors found that monosaccharide glycosides of trans-resveratrol underwent cis-trans isomerization, thereby resulting in the isomerization of about 15% of the trans-form to the cis-form.Moreover, as shown in NPL 1, since cis-resveratrol is ...

Подробнее
Номер записи: 55
08-03-2018 дата публикации

RHAMNOLIPID SYNTHESIS

Номер: US20180066297A1
Автор: BECK Simon, Buchholz Stefan, BÜLTER Thomaas, Haas Thomas
Принадлежит: EVONIK DEGUSSA GmbH

There is provided a method of producing at least one rhamnolipid comprising: 111-. (canceled)13. The method of claim 12 , wherein said organic radicals are alkyl radicals that are optionally branched claim 12 , optionally substituted claim 12 , and optionally unsaturated.14. The method of claim 13 , wherein at least one alkyl radical is hydroxy-substituted.15. The method of claim 13 , wherein at least one alkyl radical is mono- claim 13 , di- or tri-unsaturated.16. The method of claim 12 , wherein said identical or different organic radicals comprise 5 to 13 carbon atoms.17. The method of claim 12 , wherein said carbon source is an alkane selected from the group consisting of: hexane; heptane; octane; nonane; and decane; and/or an alkanoic acid selected from the group consisting of: hexanoic acid; haptanoic acid; octanoic acid; nonanoic acid; and decanoic acid.18. The method of claim 12 , wherein the recombinant cell has been genetically modified such that claim 12 , compared to the wild-type cell claim 12 , the recombinant cell has an increased activity of enzyme E claim 12 , wherein Eis an oxidoreductase.19. The method according to claim 18 , wherein the oxidoreductase is selected from the group consisting of: alkB-type oxidoreductase; monooxygenase; and NAD(P)H dependent alcohol dehydrogenase (ADH).20. The method of claim 19 , wherein the carbon source is hexane and/or decane.21. The method of claim 12 , wherein at least 40% by weight of the total carbon content in the medium is hexane claim 12 , decane claim 12 , hexanoic acid and/or decanoic acid.22. The method of claim 12 , wherein:{'sub': '1', 'a) enzyme Eis able to catalyse the conversion of 3-hydroxyalkanoyl-ACP via 3-hydroxyalkanoyl-3-hydroxyalkanoic acid-ACP to hydroxyalkanoyl-3-hydroxyalkanoic acid;'}{'sub': '2', 'b) enzyme Eis able to catalyse the conversion of dTDP-rhamnose and 3-hydroxyalkanoyl-3-hydroxyalkanoate to α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate; and'}{'sub': '3', 'c) enzyme ...

Подробнее
Номер записи: 56
17-03-2016 дата публикации

BIOCATALYTIC PRODUCTION OF NUCLEOSIDE ANALOGUES AS ACTIVE PHARMACEUTICAL INGREDIENTS

Номер: US20160076070A1
Автор: DERONCELÉ THOMAS Víctor Manuel, Montilla Arevalo Rafael, Pascual Gilabert Marta
Принадлежит:

A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula I 3. The process according to wherein the APIs or intermediates thereof produced are selected from: Clofarabine (Cl-F-araA) claim 1 , Decitabine (aza-dCyd) claim 1 , Cytarabine (ara-C) claim 1 , Vidarabine claim 1 , Brivudine claim 1 , Enocitabine (BH-AC) claim 1 , Zalcitabine (ddC) claim 1 , Cladribine (Cl-dAdo) claim 1 , Fludarabine (F-araA) claim 1 , Nelerabine (MAY) claim 1 , Zidovudine claim 1 , Floxuridine (FUDR) claim 1 , β-Thymidine claim 1 , idoxuridine (IdU) claim 1 , trifluridine (TFT) claim 1 , acedurid (EdU) claim 1 , ribavirin claim 1 , didanosine (ddl) and Pentostatin.4. The process according to wherein the APIs or intermediates thereof produced are selected from: Clofarabine claim 3 , Cytarabine claim 3 , Vidarabine claim 3 , Brivudine claim 3 , Enocitabine claim 3 , Zalcitabine claim 3 , Cladribine claim 3 , Fludarabine claim 3 , Nelerabine claim 3 , Zidovudine claim 3 , Floxuridine and Pentostatin.5. The process according to wherein the APIs or intermediates thereof produced are selected from Clofarabine claim 3 , Cytarabine and Zidovudine.6. The process according to wherein the API claim 1 , or intermediates thereof claim 1 , produced is Clofarabine.7Lactobacillus delbrueckiiLactobacillus leichmannii. The process according to any of to wherein the enzyme having NDT activity is a NDT isolated from (formerly called ).8Lactococcus lactis.. The process according to any of to wherein the enzyme having NDT activity is a NDT isolated from9. The process according to wherein the NDT is obtained from{'i': Lactobacillus delbrueckii', 'Lactobacillus leichmannii, 'a) (formerly called ) nucleotide sequence shown in SEQ ID NO. 1; or'}b) a nucleotide sequence which is the complement of SEQ ID. NO:1; orc) a nucleotide sequence which is degenerate with SEQ ID. NO:1; ord) a ...

Подробнее
Номер записи: 57
16-03-2017 дата публикации

NOVEL COMPOSITION FOR ASTRINGIN PRODUCT

Номер: US20170073720A1
Автор: Cha Gun Su, Joung Young-Hee, Kang Hyung-Sik, Yun Chul-Ho
Принадлежит:

Provided is a composition for producing astringin among metabolites of polydatin, wherein the astringin may be mass-produced by oxidizing the polydatin using a CYP102A1 chimera and mutants thereof as a catalyst, the CYP102A1 chimera being produced by fusing a reductase domain of a wild-type CYP102A1 which is a bacterial cytochrome P450 enzyme, with a heme domain of a CYP102A1 mutant. 1. A composition for producing astringin comprising at least one enzyme of the group consisting of mutants of CYP102A1 chimera and the CYP102A1 chimera , and producing astringin by oxidizing polydatin ,wherein the CYP102A1 chimera is R47L/F81I/F87V/E143G/L188Q/E267V/A475V/E559D/T665A/P676L/A679E/E688A/A742G/K814E/R826S/R837H/E871N/1882V/E888G/P895S/S955N/M968V/Q982R/A1009D/H1022Y/Q1023E of a CYP102A1 mutant, the CYP102A1 mutant is R47L/F81I/F87V/E143G/L188Q/E267V of a wild-type CYP102A1, and the mutant of CYP102A1 chimera is at least one selected from the group consisting of F11L/R47L/F81I/F87V/Q10P/E143G/L188Q/R190Q/E267V, R47L/F81I/F87V/L103F/D136G/E143G/N159S/L188Q/E267V, and R47L/F81I/F87V/M112T/E143G/L188Q/E267V/M417T of the CYP102A1 chimera.2. A kit for producing astringin comprising at least one enzyme of the group consisting of mutants of CYP102A1 chimera and the CYP102A1 chimera , and an NADPH-generating system , and producing astringin by oxidizing polydatin ,wherein the CYP102A1 chimera is R47L/F81I/F87V/E143G/L188Q/E267V/A475V/E559D/T665A/P676L/A679E/E688A/A742G/K814E/R826S/R837H/E871N/1882V/E888G/P895S/S955N/M968V/Q982R/A1009D/H1022Y/Q1023E of a CYP102A1 mutant, the CYP102A1 mutant is R47L/F81I/F87V/E143G/L188Q/E267V of a wild-type CYP102A1, and the mutant of CYP102A1 chimera is at least one selected from the group consisting of F11L/R47L/F81I/F87V/Q110P/E143G/L188Q/R190Q/E267V, R47L/F81I/F87V/L103F/D136G/E143G/N159S/L188Q/E267V, and R47L/F81I/F87V/M112T/E143G/L188Q/E267V/M417T of the CYP102A1 chimera.3. A method for producing astringin comprising:reacting at least one ...

Подробнее
Номер записи: 58
05-06-2014 дата публикации

Compound Amycolamicin, Method for Producing the Same, and Use of the Same

Номер: US20140155586A1
Автор: Homma Yoshiko, IGARASHI Masayuki, Sawa Ryuichi
Принадлежит:

A compound having a structure expressed by the following Structural Formula (1), tautomers thereof, or salts of the compound or the tautomers. 3Amycolatopsis. The method according to claim 2 , wherein the microorganism is a microorganism of sp. MK575-fF5 strain deposited under accession number FERM P-21465.5Amycolatopsis. The microorganism according to claim 4 , wherein the microorganism is a microorganism of sp. MK575-fF5 strain deposited under accession number FERM P-21465. This is a continuation application of PCT/JP2009/058210, filed on Apr. 24, 2009.1. Field of the InventionThe present invention relates to a new compound having an excellent antibacterial activity against a wide variety of pathogenic bacteria such as drug-resistant bacteria and bacteria causing pneumonia in domestic livestock, a method for producing the new compound, use of the new compound, and a new microorganism that produces the new compound.2. Description of the Related ArtIn general, infectious diseases caused by pathogenic bacteria are treated with chemotherapy including administering drugs such as antibiotics. However, conventionally, frequent use of such drugs has allowed pathogenic bacteria to acquire an ability to neutralize these drugs, leading to appearance of resistant bacteria to which the drugs are ineffective. Actually, many drug-resistant bacteria have been problematic mainly in medical facilities.For example, as one clinically important problem, , which is known as bacteria causing suppurative diseases, pneumonia and food poisoning, acquires multidrug resistances to methicillin or other antibiotics to be methicilline-resistant (MRSA). At present, vancomycin, teicoplanin, arbekacin, line zolid, etc. are used as typical therapeutic drugs against MRSA. However, it is generally difficult to completely eliminate MRSA. In particular, thorough care should be taken about the use of vancomycin, since appearance of vancomycin resistant (VRSA) has already been reported (see Sievert D M, ...

Подробнее
Номер записи: 59
18-03-2021 дата публикации

Method for preparing rhamnolipids

Номер: US20210079436A1
Автор: Guneet Kaur, Woon Chung Jonathan Wong
Принадлежит: Hong Kong Baptist University HKBU

The present disclosure relates to a method for producing rhamnolipids.

Подробнее
Номер записи: 60
18-03-2021 дата публикации

CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION

Номер: US20210079438A1
Автор: Huang Tom Tao
Принадлежит:

The invention provides novel carbohydrate esters, in particular disaccharide esters, and the methods of their preparation. These compounds find use as microbial media components for the induction of gene expression in microbial fermentation processes. 2. The method according to claim 1 , wherein an optional conventional inducer is added to the culture.3. The method according to claim 2 , wherein the optional conventional inducer comprises lactose claim 2 , cellobiose claim 2 , sophorose claim 2 , cellulose claim 2 , cellulose hydrolysate claim 2 , maltose claim 2 , isomaltose claim 2 , maltodextrins claim 2 , starch claim 2 , or starch hydrolysate.4. The method according to claim 1 , wherein the protein of interest is cellulase or amylase.5. The method according to claim 1 , wherein the protein of interest is a homologous or heterologous protein.6. The method according to claim 5 , wherein the homologous or heterologous protein is an enzyme claim 5 , a hormone claim 5 , a growth factor claim 5 , a cytokine or an antibody.7. The method according to claim 1 , wherein the fermentation host is capable of producing cellulase or amylase.8Trichoderma, Humicola, Pleurotus, Fusarium, Aspergillus, Streptomyces, Thermomonospora, Bacillus, Cellulomonas, Penicillium, Basidiomycete, Chrysoporium, Pestalotiopsis, Neurospora, Cephalosporium, Achlya, Podospora, Endothia, Mucor, Cochliobolus, Myceliopthora, TalaromycesPyricularia.. The method according to claim 1 , wherein the fermentation host is a filamentous fungus or bacteria or other hosts selected from the genus group consisting of claim 1 , and9Trichoderma reeseiAspergillus niger.. The method according to claim 1 , wherein the fermentation host is the filamentous fungus or10. The method according to claim 1 , wherein the fermentation host is grown in a liquid culture or on a solid substrate without free-flowing liquid.11. The method according to claim 1 , wherein the fermentation host has a promoter operably linked to a gene ...

Подробнее
Номер записи: 61
24-03-2016 дата публикации

Maltobionate As Antioxidant in Food Products

Номер: US20160081387A1
Автор: Per Munk Nielsen
Принадлежит: Novozymes AS

Maltobionate has an antioxidative effect in food and feed products. The antioxidant can be produced directly from starch or maltose already present in the food product, using enzymatic catalyzed processes. The antioxidant production can be performed on an isolated fraction of a food product from which it can be added back to the food production process or the final food product. Alternatively, the antioxidant can be produced as an integrated part of the food production process by adding the relevant enzymes to the process.

Подробнее
Номер записи: 62
14-03-2019 дата публикации

Biosynthetic production of steviol glycosides and processes therefore

Номер: US20190078102A1
Автор: Beihua ZHANG, David BYUN, Guohong Mao, Jacob Edward Vick, Michael Batten, Xiaodan Yu, Yang Luo, Yilin Wu
Принадлежит: Conagen Inc

The present invention relates to the production of steviol glycoside rebaudiosides D4, WB1 and WB2 and the production of rebaudioside M from Reb D4.

Подробнее
Номер записи: 63
24-03-2016 дата публикации

Modified Plants for Producing Aroma/Fine/Specialty Chemicals

Номер: US20160083742A1
Автор: Costa Michael A., Davin Laurence B., Lewis Norman G.
Принадлежит: WASHINGTON STATE UNIVERSITY

The present disclosure describes genetically modified plants that contain one or more exogenous genes associated with aroma/fine/specialty compound biosynthesis, which are capable of producing aroma/fine/specialty compounds. 182-. (canceled)83. A modified plant comprising one or more exogenous polynucleotides encoding one or more enzymes associated with an aroma compound biosynthesis , a fine compound biosynthesis , a specialty compound biosynthesis or a combination thereof.84. The modified plant of claim 83 , wherein the one or more enzymes is a synthase claim 83 , a reductase claim 83 , a transferase claim 83 , or a combination thereof.85. The modified plant of claim 84 , whereinthe synthase is a phenylacetaldehyde synthase, a propenylphenol synthase, an allylphenol synthase, a biologically active fragment or variant thereof or a combination thereof;the reductase is a phenylacetaldehyde reductase or a biologically active fragment or variant thereof; andthe transferase is an acyl transferase or a biologically active fragment or variant thereof86Larrea tridentateLarrea tridentata. The modified plant of claim 85 , wherein the propenyl phenol synthase is propenylphenol synthase or a biologically active fragment or variant thereof and the allylphenol synthase is allylphenol synthase or a biologically active fragment or variant thereof.87. The modified plant of claim 83 , wherein the aroma compounds include at least one or more metabolites associated with 2-phenyl ethanol synthesis.88. The modified plant of claim 83 , wherein the modified plant produces a 2-phenyl ethanol claim 83 , an allyl phenol claim 83 , a propenyl phenol or a combination thereof.89. The modified plant of claim 83 , wherein the modified plant is selected from the group consisting of a poplar claim 83 , a poplar hybrid claim 83 , an aspen claim 83 , and a red alder.90. The modified plant of claim 83 , wherein the modified plant produces aroma compounds that are sequestered in the modified plant as ...

Подробнее
Номер записи: 64
23-03-2017 дата публикации

MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF

Номер: US20170081690A1
Автор: Kahne Suzanne Walker, Ostash Bohdan Omelyanovich
Принадлежит: President and Fellows of Harvard College

The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes. 111-. (canceled)12. A method of synthesizing a moenomycin , a moenomycin derivative , or a moenomycin intermediate wholly or partially in vitro comprising: reacting a one or more moenomycin precursor , derivative and/or moenomycin intermediate with a one or more polypeptide selected from the group consisting of: moeA4 , moeB4 , moeC4 , moeB5 , moe A5 , moeD5 , moeJ5 , moeE5 , moeF5 , moeH5 , moeK5 , moeM5 , moeN5 , moe05 , moeX5 , moeP5 , moeR5 , moeS5 , moeGT1 , moeGT2 , moeGT3 , moeGT4 , and moeGT5 , under conditions wherein the moenomycin , the moenomycin derivative , or the intermediate is wholly or partially synthesized.13. A method of modifying a moenomycin wholly or partially in vitro comprising: reacting a moenomycin , a moenomycin derivative or a moe intermediate with a one or more polypeptide selected from the group consisting of: moeA4 , moeB4 , moeC4 , moeB5 , moe A5 , moeD5 , moeJ5 , moeE5 , moeF5 , moeH5 , moeK5 , moeM5 , moeN5 , moeO5 , moeX5 , moeP5 , moeR5 , moeS5 , moeGT1 , moeGT2 , moeGT3 , moeGT4 , and moeGT5 , under conditions wherein the moenomycin , the moenomycin derivative , or the moenomycin intermediate is modified.1415-. (canceled)17. The moenomycin derivative of claim 16 , wherein R and Rindependently are —NH.19. (canceled)2122-. (canceled)24. The moenomycin derivative of claim 23 , wherein R3 is hydrogen or hydroxyl.25. (canceled)2728-. (canceled)3031-. (canceled)3334-. (canceled)3637-. (canceled)3943-. (canceled)44. A pharmaceutical composition comprising the moenomycin derivative of and a pharmaceutically acceptable carrier.4648-. (canceled)49. A ...

Подробнее
Номер записи: 65
29-03-2018 дата публикации

VACCINE COMPOSITIONS AGAINST PATHOGENIC FUNGI AND METHODS FOR USE THEREOF

Номер: US20180085442A1
Автор: DEL POETA Maurizio, RELLA Antonella
Принадлежит:

The present disclosure provides compositions comprising mutant fungi include an inactive form of the sterylglucosidase enzyme. The present disclosure is also directed to vaccine based compositions, which include a mutant fungus that prohibit pathogenic fungal infection. This disclosure also provides methods for administering these compositions as a prophylaxis against fungal infection, as well as methods for isolating sterylglucosides that include the use of such mutant fungal compositions. 1. A composition comprising a mutant fungus , wherein said mutant fungus comprises an inactivated Sterylglucosidase (Sgl1) gene or homolog thereof.2. The composition of claim 1 , wherein said mutant fungus lacks the ability to metabolize sterylglucosides (SGs).3. The composition of claim 1 , wherein said mutant fungus accumulates sterol glycosides.4. The composition of claim 1 , wherein said mutant fungus is avirulent.5Cryptococcus. The composition of claim 1 , wherein said mutant fungus is from a genus.6Cryptococcus neoformans, Cryptococcus gatii, Cryptococcus albidus, Cryptococcus uniguttulatus, Candida albicans, Aspergillus fumigatus. The composition of claim 1 , wherein said mutant fungus is selected from the group consisting of and other fungi in which the Sgl1 gene is deleted.7. A method for producing sterylglucosides comprising:providing a mutant fungus comprising an inactivated Sterylglucosidase (Sgl1) gene or homolog thereof;expressing said mutant fungus in a fungal cell, wherein said fungal cell produces sterylglucosides; andisolating said sterylgucosides.8. The method of claim 7 , wherein said mutant fungus lacks the ability to metabolize sterylglucosides (SGs).9. The method of claim 7 , wherein said mutant fungus accumulates sterol glycosides.10Cryptococcus. The method of claim 7 , wherein said mutant fungus is from a genus.11Cryptococcus neoformans, Cryptococcus gatii, Cryptococcus albidus, Cryptococcus uniguttulatus, Candida albicans, Aspergillus fumigatus. The ...

Подробнее
Номер записи: 66
30-03-2017 дата публикации

Use of ginsenoside m1 for inhibiting renal fibrosis

Номер: US20170087170A1
Автор: Ann Chen, Kuo-Feng Hua, Sheau-Long Lee, Shuk-Man Ka, Yu-Chieh Lee
Принадлежит: Wellhead Biological Technology Corp

The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.

Подробнее
Номер записи: 67
02-04-2015 дата публикации

Polyphenol, terpenoid, glycoside, and alkaloid production by crocus sativus cell cultures

Номер: US20150093776A1
Автор: Colby G. Caldwell, Raymond E. B. Ketchum, Sung-Yong H. Yoon
Принадлежит: Dianaplantsciences SAS

A method for producing metabolites of Crocus sativus ( C. sativus ) includes (i) selecting a cell line of C. sativus that produces one or more saffron metabolites in cell suspension culture, and (ii) growing the selected cell line in a suspension cell culture to produce the saffron metabolite.

Подробнее
Номер записи: 68
19-03-2020 дата публикации

HIGH-PURITY RUBUSOSIDE AND PROCESS FOR PRODUCING OF THE SAME

Номер: US20200087694A1
Автор: MARKOSYAN Avetik
Принадлежит:

The invention provides a process of producing Rubusoside from steviol glycosides of plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. 1Stevia rebaudiana. A process for preparing Rubusoside from steviol glycosides of comprising the steps of:a. providing a solution comprising Stevioside;b. providing an enzyme composition comprising at least one enzyme selected from the group comprising rhamnosidase, β-glucosidase, β-glucanase, hesperidinase, naringinase, pectinase, cellulase, hemicellulase, xylanase;c. adding the enzyme composition to the solution comprising Stevioside to obtain reaction mixture;d. incubating the reaction mixture to facilitate complete or partial transformation of Stevioside to Rubusoside;e. recovering and purifying high purity Rubusoside from reaction mixture.2. A process of wherein step (a) the concentration of Stevioside is 1-50% (wt/vol) claim 1 , preferably 5-30% (wt/vol) claim 1 , more preferably 8-10% (wt/vol).3. A process of wherein step (d) the molar yield of Rubusoside from Stevioside is 1-100% claim 1 , preferably 80-100% and more preferably 95-100%.4. A process of wherein step (e) at least one purification techniques is employed selected from the group comprising ion exchange treatment claim 1 , macroporous adsorbent treatment claim 1 , membrane process claim 1 , chromatographic separation claim 1 , and crystallization from various solvent systems.5. A process of wherein step (e) the recovery and purification of Rubusoside comprises the steps of:a. providing reaction mixture containing Rubusoside;b. contacting the reaction mixture ...

Подробнее
Номер записи: 69
06-04-2017 дата публикации

Methods of Producing Rhamnolipids

Номер: US20170096695A1
Автор: Engel Philip, Gehring Christian, Schaffer Steffen, Thum Oliver, Wessel Mirja
Принадлежит:

The present invention relates to a method of preparing at least one rhamnolipid comprising: 115-. (canceled)17. The method of claim 16 , wherein the Cmolecule is selected from the group consisting of: butane; 1-butanol; 2-butanol; 1-butanal; butanone; butyric acid; and combinations thereof.18. The method of claim 16 , wherein the cell has been genetically modified such that claim 16 , compared to the wild-type of the cell claim 16 , the cell has an increased activity of an oxidoreductase.19. The method of claim 18 , wherein the oxidoreductase is selected from the group consisting of: alkB-type oxidoreductase; monooxygenase; and NAD(P)H dependent alcohol dehydrogenase (ADH).20. The method of claim 16 , wherein the recombinant cell has an increased activity of the enzymes E1 claim 16 , E2 claim 16 , E3 and oxidoreductase compared to the wild-type of the cell and wherein the C4 molecule is butane.21. The method of claim 16 , wherein said recombinant cell is in a medium in which at least 40% by weight of the total carbon content of the medium is C4 molecules.22. The method of claim 16 , wherein:{'sub': '1', 'a) the enzyme Eis able to catalyze the conversion of 3-hydroxyalkanoyl-ACP via 3-hydroxyalkanoyl-3-hydroxyalkanoic acid-ACP to hydroxyalkanoyl-3-hydroxyalkanoic acid;'}{'sub': '2', 'b) the enzyme Eis able to catalyze the conversion of dTDP-rhamnose and 3-hydroxyalkanoyl-3-hydroxyalkanoate to α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate; and'}{'sub': '3', 'c) the enzyme Eis able to catalyze the conversion of dTDP-rhamnose and α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate to α-L-rhamnopyranosyl-(1-2)-α-L-rhamnopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.'}24Aspergillus; Corynebacterium; Brevibacterium; Bacillus; Acinetobacter; Alcaligenes; Lactobacillus; Paracoccus; Lactococcus; Candida; Pichia; Hansenula; Kluyveromyces; Saccharomyces; Escherichia; Zymomonas; Yarrowia; Methylobacterium; Ralstonia; Pseudomonas; Rhodospirillum; Rhodobacter; ...

Подробнее
Номер записи: 70
26-06-2014 дата публикации

Process for producing a particulate composition comprising anhydrous crystalline 2-o-alpha-d-glucosyl-l-ascorbic acid

Номер: US20140178943A9
Автор: Seisuke Izawa, Shigeharu Fukuda, Takashi Shibuya, Tomoyuki Nishimoto, Toshio Miyake
Принадлежит: Hayashibara Co Ltd

The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside.

Подробнее
Номер записи: 71
14-04-2016 дата публикации

Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation

Номер: US20160101186A1
Автор: Jain Sanjay, PAPAIOANNOU Ioannis, THOBHANI Smita
Принадлежит: Lipoxen Technologies Limited

Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. 1. A process of making an activated polysialic acid (PSA) molecule comprising a terminal sialic acid unit at the reducing end , the process comprising:a) reducing the reducing terminal sialic acid unit to form a vicinal diol group;b) selectively oxidizing the vicinal diol group of step (a) to form an aldehyde group;c) aminating the aldehyde group of step (b) to form an amine group; andd) reacting the amine group of step (c) with a bifunctional reagent comprising two amine-reactive functional groups to form an activated PSA molecule, the activated PSA molecule being monofunctional and comprising an amine-reactive group at the reducing end.2. The process of claim 1 , wherein the PSA molecule includes PSA molecules consisting substantially only of units of sialic acid or PSA molecules comprising sialic acid units alternating with other saccharide unit.3. The process of claim 2 , wherein the PSA molecules consisting substantially only of units of sialic acid alpha-2 claim 2 ,8 PSA molecules and/or alpha-2 claim 2 ,9 linked PSA molecules.4. The process of claim 1 , wherein the PSA molecule comprises at least 5 sialic acid units.5. The process of claim 4 , wherein the PSA molecule comprises at least 10 sialic acid units.6. The process of claim 5 , wherein the PSA molecule comprises at least 50 sialic acid units.7. The process of claim 1 , wherein in step (a) the reducing agent used is a hydrite or hydrogen with catalysts.8. The process of claim 7 , wherein the hydrite is an alkali metal hydride.9. The process of claim 1 , wherein ...

Подробнее
Номер записи: 72
14-04-2016 дата публикации

PRODUCTION OF DIRHAMNOSE-LIPID IN RECOMBINANT NONPATHOGENIC BACTERIUM PSEUDOMONAS CHLORORAPHIS

Номер: US20160102330A1
Автор: ASHBY Richard D., GUNTHER Nereus W., Solaiman Daniel, Zerkowski Jonathan A.
Принадлежит:

NRRL B-30761 produces monorhamnolipids with predominantly 3-hydroxydodecenoyl-3-hydroxydecanoate (C-C) or 3-hydroxydodecanoyl-3-hydroxydecanoate (C-C) as the lipid moiety under static growth conditions. The cloning and sequencing of three genes and proteins involved in the biosynthesis of monorhamnose-lipid (RL) is described. Expression of two of these genes, i.e., rhlA and rhlB, together in NRRL B-30761 increases RL production by at least 10-fold. Also the generation of a recombinant NRRL B-30761 capable of synthesizing dirhamnose-lipid (RL) is described. Characterization of RL and RL produced by the recombinant NRRL B-30761 is also described. 166-. (canceled)67Pseudomonas. A recombinant Pseudomonas chlororaphis comprising an expression vector , wherein said expression vector further comprises a promoter operably linked to a heterologous polynucleotide encoding rhamnosyltransferase C.68Pseudomonas chlororaphisPseudomonas. The recombinant of wherein said rhamnosyltransferase C has the amino acid sequence of SEQ ID NO: 26.69Pseudomonas chlororaphisPseudomonas. The recombinant of wherein said rhamnosyltransferase C has the nucleotide sequence of SEQ ID NO: 25.70Pseudomonas chlororaphisPseudomonas chlororaphisP. chlororaphis. The recombinant of wherein said is NRRL B-30761.71. A method of producing dirhamnose-lipid comprising{'i': Pseudomonas chlororaphis', 'Pseudomonas rhamnosyltransferase', 'P. chlororaphis,', 'P. chlororaphis, 'transforming a wild-type with an expression vector comprising a promoter operably linked to DNA encoding a C to generate a recombinant wherein said wild-type produces rhamnosyltransferase A and rhamnosyltransferase B;'}{'i': P. chlororaphis', 'Pseudomonas, 'isolating recombinant that produces said rhamnosyltransferase C; and'}{'i': 'P. chlororaphis', 'culturing said isolated recombinant in medium capable of supporting rhamnose-lipid biosynthesis.'}72Pseudomonas. The method of wherein said rhamnosyltransferase C has the amino acid sequence of ...

Подробнее
Номер записи: 73
13-04-2017 дата публикации

METHODS OF GANGLIOSIDE PRODUCTION

Номер: US20170101657A1
Автор: RAGAGLIA Vanessa, Sharma Vandana Madanlal
Принадлежит:

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided. 1. A method of producing a ganglioside in a cell , comprising:(a) treating said cell with chloroquine to accumulate said ganglioside wherein said ganglioside is selected from the group consisting of GM1, GM2, GM3, GD1a, GD1b, GD3 and GT1; wherein said cell is selected from the group consisting of an immortalized cell, a stromal cell, and a fibroblast;', 'wherein said cell is not a PC 12 cell, an HT22 cell, a brain cell from a sheep afflicted with gangliosidosis, and fibroblast cell from sheep afflicted with gangliosidosis., '(b) isolating said ganglioside, quantifying said ganglioside, or both, from said chloroquine-treated cell;'}2. The method of claim 1 , wherein said cell is selected from the group consisting of a neuroblastoma cell claim 1 , a Chinese hamster ovary cell (CHO) claim 1 , a human embryonic kidney cell (HEK) claim 1 , a stromal cell claim 1 , and a fibroblast cell.3. The method of claim 2 , wherein said cell is a CHO cell claim 2 , wherein said CHO cell is a CHO-K1 cell.4. The method of claim 2 , wherein said cell is a HEK cell claim 2 , wherein said HEK cell is a HEK293 cell.5. The method of claim 2 , wherein said cell is a fibroblast cell.6. The method of claim 5 , wherein said fibroblast cell is a dermal fibroblast cell.7. (canceled)8. The method of claim 2 , wherein said cell is a neuroblastoma cell.9. The method of claim 8 , wherein said ...

Подробнее
Номер записи: 74
20-04-2017 дата публикации

NOVEL FLAVONOIDS O-A-GLUCOSYLATED ON THE B CYCLE, METHOD FOR THE PRODUCTION THEREOF AND USES

Номер: US20170107242A1
Автор: ANDRE Isabelle, Brison Yoan, Cambon Emmanuelle, Malbert Yannick, Morel Sandrine, Pompon Denis, Remaud-Siméon Magali, Urban Philippe
Принадлежит:

The invention relates to a method for producing derivatives of O-α-glucosylated flavonoid, comprising at least one step of incubating a glucansucrase with a flavonoid and at least one sucrose, the flavonoid being a flavonoid which is monohydroxylated or hydroxylated in a non-vicinal manner on the B cycle. The invention also relates to novel O-α-glucosylated flavonoid derivatives, and to the use thereof. 2. The process as claimed in claim 1 , wherein just one of the groups chosen from R claim 1 , R claim 1 , R claim 1 , Rand R claim 1 , preferably R claim 1 , represents a hydroxyl group claim 1 ,{'sub': 8', '9', '10', '11', '12', '1', '10', '5', '9', '4', '9', '1', '3', '2', '3', '1', '3', '2', '2', '2', '3', '1', '3', '1', '3', '1', '3', '1', '3, 'the other groups among R, R, R, Rand R, which may be identical or different, being chosen from the group comprising a hydrogen atom; a linear or branched, saturated or unsaturated C-Chydrocarbon-based group, optionally interrupted with at least one heteroatom chosen from O, N or S; a halogen atom; a C-Caryl; a C-Cheterocycle; a (C-C)alkoxy group; a C-Cacyl; a C-Calcohol; a —COOH; —NH; —CONH; —CHO; —SH; —C(O)O(C-C) group; a C-Camine; a C-Cimine; a nitrile group; a C-Chaloalkyl; and a C-Cthioalkyl; a —C(W) group; and an —O(W) group; W representing a chain consisting of from 1 to 6 glycoside(s);'}{'sub': 8', '9', '11', '12, 'the R, R, Rand Rgroups preferably representing hydrogen atoms.'}3. The process as claimed in claim 2 , wherein Rrepresents a hydroxyl group and R claim 2 , R claim 2 , Rand Rrepresent hydrogen atoms.4. The process as claimed in claim 1 , wherein:{'sub': 8', '10', '11', '12', '10, 'Rand just one of the groups chosen from R, Rand R, preferably R, represent a hydroxyl group,'}{'sub': 9', '10', '11', '12', '1', '10', '5', '9', '4', '9', '1', '3', '2', '3', '1', '3', '2', '2', '2', '3', '1', '3', '1', '3', '1', '3', '1', '3, 'Rand the other groups among R, Rand R, which may be identical or different, being ...

Подробнее
Номер записи: 75
30-04-2015 дата публикации

HIGH-PURITY RUBUSOSIDE AND PROCESS FOR PRODUCING OF THE SAME

Номер: US20150118379A1
Автор: MARKOSYAN Avetik
Принадлежит:

The invention provides a process of producing Rubusoside from steviol glycosides of plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. 1Stevia rebaudiana. A process for preparing Rubusoside from steviol glycosides of comprising the steps of:a. providing a solution comprising Stevioside;b. providing an enzyme composition comprising at least one enzyme selected from the group comprising rhamnosidase, β-glucosidase, β-glucanase, hesperidinase, naringinase, pectinase, cellulase, hemicellulase, xylanase;c. adding the enzyme composition to the solution comprising Stevioside to obtain reaction mixture;d. incubating the reaction mixture to facilitate complete or partial transformation of Stevioside to Rubusoside;e. recovering and purifying high purity Rubusoside from reaction mixture.2. A process of wherein step (a) the concentration of Stevioside is 1-50% (wt/vol) claim 1 , preferably 5-30% (wt/vol) claim 1 , more preferably 8-10% (wt/vol).3. A process of wherein step (d) the molar yield of Rubusoside from Stevioside is 1-100% claim 1 , preferably 80-100% and more preferably 95-100%.4. A process of wherein step (e) at least one purification techniques is employed selected from the group comprising ion exchange treatment claim 1 , macroporous adsorbent treatment claim 1 , membrane process claim 1 , chromatographic separation claim 1 , and crystallization from various solvent systems.5. A process of wherein step (e) the recovery and purification of Rubusoside comprises the steps of:a. providing reaction mixture containing Rubusoside;b. contacting the reaction mixture ...

Подробнее
Номер записи: 76
10-07-2014 дата публикации

SOPHOROLACTONE PRODUCTION

Номер: US20140194336A1
Автор: Develter Dirk, Fleurackers Steve
Принадлежит: ECOVER CO-ORDINATION CENTER N.V.

The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid, -continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the reaction mixture below 10 g/l, resulting in the crystallization of at least part of the sophorolactone present in the reaction mixture, -warming the reaction mixture to a temperature between 60° C. and 90° C., thereby melting the sophorolactone crystals, -allowing the molten sophorolactone to settle and to provide a crude sophorolactone composition, and -removing the crude sophorolactone composition from the remainder of the reaction mixture without use of an organic solvent. 1. Process for the selective production of sophorolactone in absence of an organic solvent , comprising the steps of:{'i': 'Candida', 'pre-cultivating cells of a species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained,'}cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid,continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the ...

Подробнее
Номер записи: 77
30-04-2015 дата публикации

CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS

Номер: US20150119561A1
Автор: Doud Emma, Gampe Christian M., Kahne Daniel Evan, Kahne Suzanne Walker, Tsukamoto Hirokazu
Принадлежит:

The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I). 2. The method of claim 1 , wherein Ris optionally substituted aliphatic.3. The method of claim 1 , wherein Ris —(CH)—C(O)R.45-. (canceled)6. The method of claim 1 , wherein Ris optionally substituted aliphatic.7. The method of claim 6 , wherein Ris methyl or —CH═CH.89-. (canceled)10. The method of claim 6 , wherein Ris substituted with halo A —CN claim 6 , —NC claim 6 , —NCO claim 6 , —OCN claim 6 , —NCS claim 6 , —SCN claim 6 , —NO claim 6 , —N claim 6 , an amino group claim 6 , a hydroxyl group claim 6 , aryl claim 6 , heteroaryl claim 6 , or optionally substituted heterocyclyl.1121-. (canceled)22. The method of claim 1 , wherein Ris —CHaryl or —CHheteroaryl.2348-. (canceled)5051-. (canceled)52. The method of claim 1 , wherein the compound of formula (III) is GalNAz claim 1 , galactosamine claim 1 , GalNAc.5354-. (canceled)55. The method of claim 1 , wherein{'sup': '1', 'sub': '2', 'Ris —C(O)NH;'}{'sup': '2', 'Ris hydrogen;'}{'sup': '3', 'Ris —OH;'}W is —O—;{'sup': '4', 'Ris hydrogen;'}{'sup': '5', 'sub': '3', 'Ris —C(O)CH;'}{'sup': '6', 'Ris —OH;'}{'sup': '7', 'Ris —OH;'}{'sup': 'a', 'Ris hydrogen; and'}{'sup': 'b', 'Ris hydrogen.'}5758-. (canceled)59. The method of claim 1 , wherein Ris C(O)NHor —CHOH.60. (canceled)61. The method of claim 1 , wherein Ris hydrogen; and Ris —OH; or Ris hydrogen; and Ris —OH.62. (canceled)63. The method of claim 1 , wherein —W—Ris —OH claim 1 , —NHC(O)NH claim 1 , —OC(O)NHor —NHC(═NH)NH.6466-. (canceled)67. The method of claim 1 , wherein Ris —C(O)CH.68. (canceled)69. The method of claim 1 , wherein Ris —OH or —OR; wherein Ris a carbohydrate moiety.70. The method of claim 1 , wherein Ris —OH.7183-. (canceled)86. A kit comprising a compound of Formula (III) and a GalT enzyme.8792-. (canceled) The present ...

Подробнее
Номер записи: 78
09-06-2022 дата публикации

ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE

Номер: US20220177940A1
Автор: Mahour Reza, Rexer Thomas F.T.
Принадлежит:

The present invention relates to an enzyme-catalyzed process for producing GDP- fucose from low-cost substrates guanosine and -fucose or guanosine and D-Mannose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Further, said process can be adapted to produce fucosylated molecules and biomolecules including glycans, such as human milk oligosaccharides, proteins, peptides, glycoproteins or glycopeptides. 2. The method according to claim 1 , wherein the solution comprises guanosine and -fucose; and{'smallcaps': L', 'L, 'the set of enzymes comprises a guanosine kinase, a polyphosphate kinase, and a -fucokinase/-fucose-1-phosphate guanylyltransferase.'}3. The method according to claim 1 , wherein the solution comprises guanosine and D-mannose; and{'smallcaps': L', 'L, 'the set of enzymes comprises a guanosine kinase, a polyphosphate kinase, and either (a) a glucokinase, phosphomannomutase, a mannose-1-phosphate guanylyltransferase, a GDP-mannose-4,6-dehydratase and a GDP--fucose- synthase or (b) an N-acetylhexosamine-1-kinase, a mannose-1-phosphate guanylyltransferase, a GDP-mannose 4,6-dehydratase and a GDP--fucose-synthase.'}4. The method according to claim 1 , wherein the set of enzymes further comprises a pyrophosphatase.5. The method according to claim 1 , wherein at least one enzyme of the set of enzymes is immobilized on a solid support.6. The method according to claim 1 , wherein the set of enzymes is co-immobilized on a solid support.7. The method according to claim 5 , wherein the at least one enzyme is immobilized on a solid support from cell lysate or the set of enzymes is co-immobilized on a solid support from cell lysate.8. The method according to claim 1 , wherein the concentration of guanosine and -fucose or guanosine and -mannose in the solution provided in A) is in the range of 0.2 mM to 5 claim 1 ,000 mM.9. The method according to claim 1 , wherein the polyphosphate is a long-chain polyphosphate having at ...

Подробнее
Номер записи: 79
13-05-2021 дата публикации

NOVEL 5'-INOSINIC ACID DEHYDROGENASE AND METHOD OF PREPARING 5'-INOSINIC ACID USING THE SAME

Номер: US20210139939A1
Автор: BAEK Min Ji, CHANG Jin Sook, LEE Ji Hye, PARK So-jung, YOON Byoung Hoon
Принадлежит:

Provided are a variant of 5′-inosinic acid dehydrogenase, a microorganism including the same, and a method of preparing 5′-inosinic acid using the same. 1. A variant of 5′-inosinic acid dehydrogenase having i) substitution of an amino acid at position 377 with threonine , ii) substitution of an amino acid at position 499 with isoleucine , or iii) substitution of the amino acid at position 377 with threonine and substitution of the amino acid at position 499 with isoleucine in an amino acid sequence of SEQ ID NO: 2.2. A polynucleotide encoding the variant of 5′-inosinic acid dehydrogenase of .3. A vector comprising the polynucleotide of .4Corynebacterium. A microorganism of the genus producing 5′-inosinic acid claim 1 , the microorganism comprising the variant of 5′-inosinic acid dehydrogenase of .5CorynebacteriumCorynebacteriumCorynebacterium stationis.. The microorganism of the genus producing 5′-inosinic acid of claim 4 , wherein the microorganism of the genus is6. A method of preparing 5′-inosinic acid claim 4 , comprising:{'i': 'Corynebacterium', 'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'culturing the microorganism of the genus of in a medium; and'}recovering 5′-inosinic acid from the microorganism or the medium.7CorynebacteriumCorynebacterium stationis.. The method of preparing 5′-inosinic acid of claim 6 , wherein the microorganism of the genus is8Corynebacterium. A microorganism of the genus producing 5′-inosinic acid claim 3 , the microorganism comprising the vector of .9CorynebacteriumCorynebacteriumCorynebacterium stationis.. The microorganism of the genus producing 5′-inosinic acid of claim 8 , wherein the microorganism of the genus is10. A method of preparing 5′-inosinic acid claim 8 , comprising:{'i': 'Corynebacterium', 'claim-ref': {'@idref': 'CLM-00008', 'claim 8'}, 'culturing the microorganism of the genus of in a medium; and'}recovering 5′-inosinic acid from the microorganism or the medium.11CorynebacteriumCorynebacterium stationis.. The ...

Подробнее
Номер записи: 80
07-05-2015 дата публикации

ONE STEP ENZYMATIC PROCESS FOR PRODUCING ALKYL FURANOSIDES

Номер: US20150125888A1
Автор: Chlubnova Ilona, Daniellou Richard, FERRIERES Vincent, Nugier-Chauvin Caroline, Pennec Alize
Принадлежит:

A process for enzymatically converting a furanoside substrate in a product of interest, includes contacting the substrate with an enzyme in presence of an alcohol acceptor, wherein the enzyme is preferably Araf51, and wherein the product is preferably an alkyl furanoside. The mutant Araf51 enzyme showing improved transglycosylation activity in comparison with the native wild-type (wt) Araf51 enzyme, and a method for screening the mutants are also described. 1. A process for enzymatically converting a furanosyl-containing polysaccharide substrate in a product of interest which is a furanoside , said process comprising contacting said substrate with an enzyme in presence of an alcohol acceptor.2. The process of being a one step process.3. The process of claim 1 , wherein the enzymatic conversion is a transglycosylation.4Clostridium thermocellumThermotoga maritimaThermobacillus xylaniliticusGeobacillus stearothermophilusAspergillus oryzaeBacillus subtilisCellvibrio japonicusStreptomyces avermitilisAspergillus kawachiiAspergillus terreus. The process of claim 1 , wherein the enzyme is selected from the group comprising proteins of the GH51 family claim 1 , such as claim 1 , for example claim 1 , Araf51 GH51 from (encoded by the nucleotide sequence SEQ ID NO: 1) claim 1 , Tm-AFase GH51 from (SEQ ID NO: 9) claim 1 , AbfD3 GH51 from (SEQ ID NO: 10) claim 1 , AbfAT-6 GH51 from (SEQ ID NO: 11) claim 1 , AbfA GH51 from (SEQ ID NO: 12); GH 43 from (SEQ ID NO: 13); Abf51A from (SEQ ID NO: 14); CBM42 GH42 from (SEQ ID NO: 15); AkabfB GH54 (SEQ ID NO: 16); and α-ara pI from (SEQ ID NO: 17).5Clostridium thermocellum. The process of claim 1 , wherein the enzyme is an Araf51 enzyme from (SEQ ID NO: 1).6. The process of claim 1 , wherein the enzyme is a native Araf51 enzyme.7. The process of claim 1 , wherein the enzyme is a mutant Araf51 enzyme claim 1 , wherein said mutant enzyme presents at least one of the following features:no inhibition in presence of alcohol acceptors; ...

Подробнее
Номер записи: 81
25-08-2022 дата публикации

Compositions And Methods For Glycosylating Cannabinoid Compounds

Номер: US20220267820A1
Автор: Goncalves Elton Carvalho, Lebrun Erick, Sayre Richard T., Travers Timothy, Willette Stephanie, Zidenga Tawanda
Принадлежит:

The present invention relates generally to the use of novel UDP-glucosyltransferases enzymes having specific activity towards cannabinoid compounds. The present invention further relates generally to the use of novel UGT enzymes having specific activity towards cannabinoid compounds to generate water-soluble cannabinoid glycoside compounds. 1. A method for producing select water-soluble cannabinoid compounds comprising the step of:providing a yeast cell expressing a heterologous nucleotide sequence, operably linked to a promoter, encoding a UDP-glucosyltransferases (UGT) having glycosylation activity towards a cannabinoid having at least one glycosylation site selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), delta-9-tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA); cannabigerol (CBG), and cannabigerolic acid (CBGA);introducing said cannabinoid having at least one glycosylation site to said yeast cell; andglycosylating said cannabinoid forming a cannabinoid glycoside.2. The method of claim 1 , wherein said step of introducing comprises the step of introducing said cannabinoid having at least one glycosylation site to a yeast cell culture.3. The method of claim 1 , wherein said UGT comprises a UGT selected from the group consisting of: SEQ ID NOs. 1-9181.4Pichia pastorisSaccharomyces cerevisiaeKluyveromyces marxianus. The method of claim 1 , wherein said yeast cell comprises a yeast cell selected from the group consisting of: a cell claim 1 , a cell claim 1 , and a cell.5. The method of claim 1 , wherein said nucleotide sequence encoding a heterologous UGT is codon optimized for expression in a yeast cell.6. A method for producing water-soluble cannabinoid compounds comprising:providing a yeast cell expressing a heterologous nucleotide sequence, operably linked to a promoter, encoding a UDP-glucosyltransferases (UGT) having glycosylation activity towards a cannabinoid;introducing said cannabinoid having at least one ...

Подробнее
Номер записи: 82
16-04-2020 дата публикации

PROCESS FOR PRODUCING A RHAMNOLIPID PRODUCED BY PSEUDOMONAS OR ENTEROBACTER USING ANDIROBA OR MURUMURU SEED WASTE

Номер: US20200115729A1
Автор: da Silva Bicalho Gabriela, de A. Rodrigues Maria Filomena, FERRARI Cintia Rosa, Leo Patricia, Maiorano Alfredo Eduardo, Ota Eliza Mami, Saito Matsubara Rosa Mitiko, Vieira Noemi Jacques
Принадлежит:

Process for producing a rhamnolipid produced by or using andiroba or murumuru seed waste, pertaining to the sector of compounds containing monosaccharide radicals, consists of producing rhamnolipids by a biotechnological process using andiroba or murumuru seed waste, following oil extraction, as a substrate for a or line cultivated in a bioreactor with a non-dispersive aeration system for reducing foam, producing a rhamnolipid content of 10.5 g/L for bacteria, in bioreactors carried out in a stirred tank with non-dispersive aeration using microporous membranes, particularly of silicone tubes, which allow oxygen to be supplied by diffusion. This type of aeration allows for various configurations, and in the embodiment of the invention, the porous membrane/tube was internally located in the liquid in the bioreactor in the form of a serpentine, under the following process conditions: pure oxygen with suitable pressure and flow rate to maintain O2 pressure in the bioreactor at 20% during the first 24 hours of the assay and stirring varying from 300 to 700 rpm, using 2 radial impellers and manual adjustment according to the decrease in the concentration of dissolved oxygen. The product produced has features that can be used primarily in the cosmetic industry due to its emulsifying, stability and non toxicity capacities. 17-. (canceled)8PseudomonasEnterobacter. A process for obtaining rhamnolipid from or using andiroba or murumuru seed residues , comprising the following steps:(a) reactivating the microorganism kept under refrigeration by means of growth in nutrient broth;(b) preparing the inoculum; and(c) batch bioprocessing in a stirred tank reactor under aeration conditions, [{'i': Pseudomonas', 'Enterobacter, 'step a) reactivates or microorganisms kept under cryopreservation refrigeration at a temperature ranging from −70 to −100° C., by growing in a nutrient broth for 10 to 30 hours, at a temperature of from 25 to 40° C., on a stirring platform at a stirring speed of ...

Подробнее
Номер записи: 83
12-05-2016 дата публикации

NOVEL COMPOUND DERIVED FROM PLANT OF GENUS QUAMOCLIT AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES

Номер: US20160130293A1
Автор: Chung Bong Hyun, LEE Ui Jin, YI So Yeon
Принадлежит: KOREA RESEARCH INSTITUTE BIOSCIENCE

The present invention provides a novel compound isolated from a plant of the genus and a method for preparing a novel compound isolated from a plant of the genus through chemical synthesis, and relates to a novel compound and a composition containing the novel compound as an active ingredient for preventing or treating diabetes and diabetic complications. The compound derived from a plant of the genus and the composition containing the compound as an active ingredient according to the present invention have an excellent effect of promoting insulin secretion, thereby exhibiting efficacies in preventing or treating diabetes and the resulting various complications. 2. The compound of claim 1 , wherein Rand Rare each independently H or Calkyl.3. The compound of claim 1 , wherein both Rand Rare H.4Quamoclit.. The compound of claim 1 , wherein the compound is derived from a plant of the genus5QuamoclitQuamoclit angulata.. The compound of claim 4 , wherein the plant of the genus is9QuamoclitQuamoclit angulata.. The method of claim 6 , wherein the plant of the genus is10. The method of claim 8 , wherein the enzymatic treatment comprises the steps of:(i) treatment with at least one enzyme selected from the group consisting of cellulase, beta-glucanase, and xylanase; and(ii) treatment with at least one enzyme selected from the group consisting of glucosidase, cellulase, galactosidase, amyloglucosidase, xylosidase, and xylanase.12. The method of claim 11 , wherein both Rand Rare H.13. The method of claim 11 , wherein the sugar in step (b) comprises at least one selected from the group consisting of glucose claim 11 , fucose claim 11 , rhamnose claim 11 , arabinose claim 11 , xylose claim 11 , quinovose claim 11 , maltose claim 11 , glucuronic acid claim 11 , ribose claim 11 , N-acetyl glucosamine claim 11 , and galactose.14. The method of claim 11 , wherein the reaction solvent comprises at least one selected from the group consisting of aliphatic or aromatic hydrocarbons ...

Подробнее
Номер записи: 84
14-05-2015 дата публикации

Method for Producing Oligosaccharides and Oligosaccharide Glycosides by Fermentation

Номер: US20150133647A1
Автор: Champion Elise, Dekany Gyula, Dureau Rémy, Hederos Markus, Peltier-Pain Pauline, Risinger Christian
Принадлежит: GLYCOM A/S

The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor. The application further discloses a method for producing an oligosaccharide comprising the steps of: (a) culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor to produce an anomerically protected glycosidic oligosaccharide derivative, then (b) removing/deprotecting the anomeric protective group. 1. A method for producing an oligosaccharide derivative having an aglycon R , wherein R is OR , which Ris a group removable by catalytic hydrogenolysis , or R is —SR , which Ris selected from optionally substituted alkyl , optionally substituted aryl and optionally substituted benzyl , or R is azide , or R is —NH—C(R″)═C(R′) , wherein each R′ independently of each other is an electron withdrawing group selected from —CN , —COOH , —COO-alkyl , —CO-alkyl , —CONH , —CONH-alkyl and —CON(alkyl) , or wherein the two R′-groups are linked together and represent —CO—(CH)—CO— and thus form with the carbon atom to which they are attached a 5-7 membered cycloalkan-1 ,3-dion , in which dion any of the methylene groups is optionally substituted with 1 or 2 alkyl groups , and R″ is H or alkyl , said method comprising the step of culturing , in a culture medium containing a lactose acceptor having the aglycon R , wherein R is as defined above , a genetically modified cell having a recombinant gene that encodes an enzyme capable of modifying said lactose acceptor or one of the ...

Подробнее
Номер записи: 85
10-05-2018 дата публикации

GLYCOSYLATED AROMA- AND FRAGRANCE PRECURSORS AND FRAGRANCE PRODUCTS THAT CAN BE ACTIVATED

Номер: US20180127681A1
Автор: Adamski Heimo, Fischer Thilo, Hinz Detlef Erich, Hoffmann Thomas, Huang Fong-Chin, Schwab Wilfried
Принадлежит:

The present invention discloses biotechnologically produced inactive aroma- and fragrance/scent precursors in new concentration ranges beyond those of natural aroma glycoside sources, which can be activated by external triggers like enzymes, temperature and p H, and then release the aroma and the fragrance. 1. Product or composition comprising at least one aroma glycoside comprising an aglycone component and at least one sugar component , wherein the concentration of the at least one aroma glycoside is higher than its concentration in natural products or compositions.2. Product or composition according to claim 1 , wherein the aroma is at least one selected from the list of compounds consisting of eugenol claim 1 , citronellol claim 1 , thymol claim 1 , carvacrol claim 1 , furaneol claim 1 , 1-hexanol claim 1 , homofuraneol claim 1 , norfuraneol claim 1 , menthol claim 1 , raspberry ketone claim 1 , maltol claim 1 , ethylmaltol claim 1 , 2-furfurylthiol claim 1 , 2-methyl-3-furanthiol claim 1 , 3-mercapto-2-pentanon claim 1 , 1-octen-3-ol claim 1 , sotolon claim 1 , 4-mercapto-4-methylpentan-2-on claim 1 , (3-methylthio)-1-propanol claim 1 , and phenylethanol claim 1 , preferably from thymol claim 1 , carvacrol claim 1 , furaneol claim 1 , homofuraneol claim 1 , norfuraneol claim 1 , raspberry ketone claim 1 , maltol claim 1 , ethylmaltol claim 1 , 2-furfurylthiol claim 1 , 2-methyl-3-furanthiol claim 1 , 3-mercapto-2-pentanon claim 1 , sotolon claim 1 , 4-mercapto-4-methylpentan-2-on claim 1 , and (3-methylthio)-1-propanol claim 1 , more preferably from carvacrol claim 1 , norfuraneol claim 1 , raspberry ketone claim 1 , 2-furfurylthiol claim 1 , 2-methyl-3-furanthiol claim 1 , 3-mercapto-2-pentanon claim 1 , sotolon claim 1 , 4-mercapto-4-methylpentan-2-on claim 1 , and (3-methylthio)-1-propanol.3. Product or composition according to claim 1 , wherein the concentration of the at least one aroma glycoside is 1-10000 ppm claim 1 , preferably 10-1000 ppm claim 1 , ...

Подробнее
Номер записи: 86
10-05-2018 дата публикации

MEANS AND METHODS FOR VITAMIN B12 PRODUCTION IN DUCKWEED

Номер: US20180127794A1
Автор: ELITUV Ehud, GLUKHMAN Vladimir
Принадлежит: HINOMAN LTD

The present invention is directed to a system and method for producing vitamin B12 enriched Duckweed Bacterial Culture (DBC) composition. The aforementioned method comprises steps of inoculating at least one Lemnoideae species and at least one vitamin B12 producing bacteria species in a volume of growth media; incubating said at least one Lemnoideae species and said at least one vitamin B12 producing bacteria species under predetermined conditions to provide a Duckweed-Bacterial Culture (DBC); determining time intervals within said plots characterized by DBC with highest vitamin B12 content; and harvesting said DBC at said predetermined time intervals, thereby providing vitamin B12 enriched DBC composition. The present invention further discloses a composition comprising a vitamin B12 enriched Duckweed-Bacterial Culture (DBC), wherein said composition comprises at least one Lemnoideae species and at least one B12 producing bacteria species, further wherein said vitamin B12 content in said composition is in the range of between about 0.01 and about 100 μg per 100 g of said DBC. 146-. (canceled)47. A method for producing vitamin B12 enriched Duckweed Bacterial Culture (DBC) composition , wherein said method comprises steps of:a. inoculating at least one Lemnoideae species and at least one vitamin B12 producing bacteria species in a volume of growth media;b. incubating said at least one Lemnoideae species and said at least one vitamin B12 producing bacteria species under predetermined conditions to provide a Duckweed-Bacterial Culture (DBC);c. plotting Lemnoideae plant biomass at said predetermined conditions against time;d. plotting bacterial count of said at least one B12 producing bacteria species at said predetermined conditions against time;e. plotting vitamin B12 content in said DBC at said predetermined conditions against time;f. determining time intervals within said plots characterized by DBC with highest vitamin B12 content; andg. harvesting said DBC at said ...

Подробнее
Номер записи: 87
03-06-2021 дата публикации

MONOESTER SUGAR DERIVATIVES AS FLAVOR MODIFIERS

Номер: US20210161189A1
Автор: CAYEUX Isabelle, DELATTRE Maxime, DI PIETRO Angela, Erni Philipp, Frerot Eric, GAILLARD Maude, LARCINESE-HAFNER Valeria
Принадлежит: FIRMENICH SA

Compositions containing monoester derivatives of the primary alcohol residue of a sugar are generally disclosed herein, as well as their use as sweetness enhancers, bitterness maskers, sourness maskers, or astringency reducers, to improve the taste profile of a flavored article. 1. A flavored article comprising a flavor-enhancing compound , wherein the flavor-enhancing compound is a monoester derivative of a primary alcohol residue of a sugar compound , which comprises a sugar moiety and an acid moiety.2. The flavored article of claim 1 , wherein the sugar moiety of the flavor-enhancing compound is a monosaccharide moiety.3. The flavored article of claim 2 , wherein the sugar moiety of the flavor-enhancing compound is a hexose moiety.4. The flavored article of claim 3 , wherein the sugar moiety of the flavor-enhancing compound is an allose moiety claim 3 , an altrose moiety claim 3 , a glucose moiety claim 3 , a mannose moiety claim 3 , a gulose moiety claim 3 , an idose moiety claim 3 , a galactose moiety claim 3 , a talose moiety claim 3 , a psicose moiety claim 3 , a fructose moiety claim 3 , a sorbose moiety claim 3 , or a tagatose moiety.5. The flavored article of claim 4 , wherein the sugar moiety of the flavor-enhancing compound is a glucose moiety.6. The flavored article of any one of to claim 4 , wherein the acid moiety of the flavor-enhancing compound is a Cfatty acid moiety.7. The flavored article of claim 6 , wherein the acid moiety of the flavor-enhancing compound is a hexanoate moiety claim 6 , an octanoate moiety claim 6 , a decanoate moiety claim 6 , a 9-decenoate moiety claim 6 , a 10-undecenoate moiety claim 6 , a dodecanoate moiety claim 6 , a 9-dodecenoate moiety claim 6 , a tetradecanoate moiety claim 6 , a hexadecanoate moiety claim 6 , an octadecanoate moiety claim 6 , an oleate moiety claim 6 , a linoleate moiety claim 6 , a linolenate moiety claim 6 , an eicosapentaenoate moiet claim 6 , or a docosahexaenoate moiety.8. The flavored article ...

Подробнее
Номер записи: 88
02-05-2019 дата публикации

GLYCOLIPOPEPTIDE BIOSURFACTANTS

Номер: US20190127411A1
Автор: Berrué Fabrice, Haltli Bradley Arnold, Kerr Russell Greig, Marchbank Douglas Hubert
Принадлежит: Croda International PLC

Surfactants based on a newly discovered class of compounds include a hydrophobic lipid oligomer covalently linked to a peptide or peptide-like chain and a carbohydrate moiety, and a serine-leucinol dipeptide linked to the lipid oligomer. Such surfactants can be used to create an oil-in-water or water-in-oil emulsion by mixing together a polar component; a non-polar component; and the surfactant. Biosurfactants of the newly discovered class can be made by isolating and culturing a microorganism which produces the biosurfactant, and then isolating the biosurfactant from the culture. A microorganism can be engineered to produce biosurfactant of this newly discovered class by expressing a set of heterologous genes involved in the biosynthesis of the biosurfactant in the microorganism. 1. A purified biosurfactant comprising a hydrophobic lipid component comprising a carboxyl end and a hydroxyl end , wherein the lipid component is covalently linked to (i) a peptide or peptide-like chain at the carboxyl end of the lipid component and (ii) a carbohydrate moiety at the hydroxyl end of the lipid component via a glycosidic linkage.2. The purified biosurfactant according to claim 1 , wherein the peptide chain comprises in the range of between 2 and 10 amino acids.3. The purified biosurfactant according to claim 1 , wherein the lipid component comprises in the range of between 1 and 6 alkanoic acid moieties4. The purified biosurfactant according to claim 1 , wherein the lipid component comprises an acyle chain claim 1 , and wherein the length of each said acyl chain is in the range of between Cto C.5. The purified biosurfactant according to claim 1 , wherein the carbohydrate moiety may be selected from saccharides including glucose claim 1 , fructose claim 1 , galactose claim 1 , mannose claim 1 , ribose claim 1 , or deoxy saccharide variants including deoxyribose claim 1 , fucose claim 1 , or rhamnose.6. The purified biosurfactant according to claim 1 , wherein the peptide or ...

Подробнее
Номер записи: 89
01-09-2022 дата публикации

Production of monoacyl mel

Номер: US20220275414A1
Автор: Atsushi Sogabe, Azusa SAIKA, Dai Kitamoto, Shuhei Yamamoto, Tokuma Fukuoka, Tomohiro Sugahara, Tomotake Morita
Принадлежит: National Institute of Advanced Industrial Science and Technology AIST, Toyobo Co Ltd

Provided is a means for efficiently producing a monoacyl MEL. This means comprises culturing a monoacyl-MEL-producing microorganism in the presence of a surfactant.

Подробнее
Номер записи: 90
21-05-2015 дата публикации

Novel cell wall polymers of enterococcus faecalis and uses thereof

Номер: US20150139998A1
Автор: Agnieszka Beczala, Christian Theilacker, Johannes Huebner, Karolina Kruszynska, Otto Holst, Stefan Geiss-Liebisch
Принадлежит: Forschungszentrum Borstel Leibniz Lungenzentrum FZB, Universitaetsklinikum Freiburg

The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.

Подробнее
Номер записи: 91
21-05-2015 дата публикации

MONOTERPENE GLYCOSYLTRANSFERASE ORIGINATING FROM HOP AND METHOD FOR USING SAME

Номер: US20150140132A1
Автор: Ono Eiichiro, Tsuruoka Nobuo
Принадлежит:

The object of the present invention is to provide -derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. 1. A protein of any one selected from the group consisting of (a) to (c) shown below:(a) a protein which consists of the amino acid sequence shown in SEQ ID NO: 2, 4 or 6;(b) a protein which consists of an amino acid sequence with deletion, substitution, insertion and/or addition of 1 to 95 amino acids in the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound; and(c) a protein which has an amino acid sequence sharing a sequence identity of 80% or more with the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound.2. The protein according to claim 1 , wherein the monoterpene compound is geraniol or linalool.3. A polynucleotide of any one selected from the group consisting of (a) to (e) shown below:(a) a polynucleotide containing the nucleotide sequence shown in SEQ ID NO: 1, 3 or 5;(b) a polynucleotide encoding a protein which consists of the amino acid sequence shown in SEQ ID NO: 2, 4 or 6;(c) a polynucleotide encoding a protein which consists of an amino acid sequence with deletion, substitution, insertion and/or addition of 1 to 95 amino acids in the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound;(d) a polynucleotide encoding a protein which has an amino acid sequence sharing a sequence identity of 80% or more with the amino acid sequence shown in SEQ ID NO: 2, 4 or 6 and which has glycosylation activity on a monoterpene compound; and(e) a polynucleotide which is hybridizable under high stringent conditions with a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3 or 5 and which encodes a protein having glycosylation activity on a monoterpene compound ...

Подробнее
Номер записи: 92
23-04-2020 дата публикации

Recombinant Production of Steviol Glycosides

Номер: US20200123583A1
Автор: Hansen Halkjaer Esben, Hansen Jorgen, Hicks Paula, Houghton-Larsen Jens, Mikkelsen Dalgaard Michael, Naesby Michael, Simon Ernesto, Tange Ostergaard Thomas, Tavares Sabina
Принадлежит:

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express recombinant genes encoding UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol glycosides, e.g., Rebaudioside A and/or Rebaudioside D, which can be used as natural sweeteners in food products and dietary supplements. 1. A method for producing a target steviol glycoside or a target steviol glycoside composition , comprising contacting a starting composition comprising a steviol , a precursor steviol glycoside having a 13-O-glucose , a 19-O-glucose , or both a 13-O-glucose and a 19-O-glucose , and/or a mixture thereof with a first uridine 5′-diphospho (UDP) glycosyl transferase polypeptide capable of beta 1 ,2 glycosylation of a C2′ of the 13-O-glucose , the 19-O-glucose , or both the 13-O-glucose and the 19-O-glucose of the precursor steviol glycoside and one or more UDP-sugars , under suitable reaction conditions to transfer one or more sugar moieties from the one or more UDP-sugars to the steviol , the precursor steviol glycoside , and/or the mixture thereof , thereby producing the target steviol glycoside or the target steviol glycoside composition;wherein the first 5′-UDP glycosyl transferase polypeptide is capable of converting Rebaudioside A (RebA) to Rebaudioside D (RebD) at a rate that is at least 20 times faster than the rate at which a UDP glycosyl transferase polypeptide having the amino acid sequence set forth in SEQ ID NO:5 is capable of converting RebA to RebD under corresponding reaction conditions; and/orwherein the first 5′-UDP glycosyl transferase polypeptide is capable of converting higher amounts of RebA to RebD compared to the UDP glycosyl transferase polypeptide having the amino acid sequence set forth in SEQ ID NO:5 under corresponding reaction conditions.2. A method of transferring a second sugar moiety to a C2′ of the 13-O-glucose , the 19-O-glucose , or both the 13-O-glucose and the 19-O-glucose ...

Подробнее
Номер записи: 93
08-09-2022 дата публикации

BIOSURFACTANT-PRODUCING RECOMBINANT MICROORGANISM

Номер: US20220282296A1
Автор: FUKUOKA Tokuma, KITAMOTO Dai, KOIKE Hideaki, MORITA Tomotake, SAIKA Azusa, Sogabe Atsushi, SUGAHARA Tomohiro, Yamamoto Shuhei
Принадлежит:

Provided is a means for increasing mannosylerythritol lipid (MEL) production efficiency. The present invention is a mannosylerythritol-lipid-producing microorganism transformed with an expression vector having a gene that encodes a lipase under the control of E5Pgap promoter or E5Ptef promoter. 1. A mannosylerythritol-lipid-producing microorganism transformed with an expression vector containing a gene that encodes a lipase under the control of E5Pgap promoter or E5Ptef promoter.2Pseudozyma.. The mannosylerythritol-lipid-producing microorganism according to claim 1 , wherein the mannosylerythritol-lipid-producing microorganism is a microorganism of the genus3Pseudozyma.. The mannosylerythritol-lipid-producing microorganism according to claim 1 , wherein the gene that encodes a lipase is derived from a microorganism of the genus4Pseudozyma tsukubaensis.. The mannosylerythritol-lipid-producing microorganism according to claim 1 , wherein the mannosylerythritol-lipid-producing microorganism is5. An expression vector containing a gene that encodes a lipase under the control of E5Pgap promoter or E5Ptef promoter.6Pseudozyma.. The expression vector according to claim 5 , wherein the gene that encodes a lipase is derived from a microorganism of the genus7. The expression vector according to claim 5 , which is an expression vector for transforming a mannosylerythritol-lipid-producing microorganism.8. A method for producing a transformed mannosylerythritol-lipid-producing microorganism claim 5 , the method comprising transforming a mannosylerythritol-lipid-producing microorganism with the expression vector of .9. A method for producing a mannosylerythritol lipid using the mannosylerythritol-lipid-producing microorganism of .10. A method for producing a mannosylerythritol lipid claim 1 , the method comprising culturing the mannosylerythritol-lipid-producing microorganism of in a medium containing a vegetable oil. A technique for producing a biosurfactant by using a ...

Подробнее
Номер записи: 94
09-05-2019 дата публикации

COMPOSITIONS AND METHODS FOR THE BIOSYNTHESIS OF VANILLIN OR VANILLIN BETA-D-GLUCOSIDE

Номер: US20190136270A1
Автор: Hamilton William D.O., Hansen Esben Halkjaer, HANSEN Joergen, Heal Jonathan R., POLUR Honey, Sheridan Joseph M.
Принадлежит:

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside. 1. A method for producing vanillin and/or vanillin beta-D-glucoside comprising(a) providing a recombinant host capable of producing vanillin, wherein said recombinant host harbors a heterologous nucleic acid encoding a mutant Catechol-O-Methyl Transferase (COMT) polypeptide;(b) cultivating said recombinant host for a time sufficient for said recombinant host to produce vanillin and/or vanillin glucoside; and(c) isolating vanillin and/or vanillin glucoside from said recombinant host or from the cultivation supernatant, thereby producing vanillin and/or vanillin beta-D-glucoside.2. The method of claim 1 , wherein the mutant COMT polypeptide is capable of catalyzing methylation of an —OH group of protocatechuic acid claim 1 , wherein said methylation results in generation of at least 4 times more vanillic acid compared to iso-vanillic acid.3. The method of claim 1 , wherein the mutant COMT polypeptide has an amino acid sequence sharing at least 80 percent sequence identity with SEQ ID NO:27 determined over the entire length of SEQ ID NO:27; and which has an amino sequence which differs from SEQ ID NO:27 by at least one amino acid residue.4. The method of claim 1 , wherein the mutant COMT polypeptide comprises 1 to 10 amino acid substitutions in the amino acid sequence set forth in SEQ ID NO:27.5. The method of claim 1 , wherein the mutant COMT polypeptide comprises an amino acid having a lower hydropathy index than leucine at position 198 of SEQ ID NO:27.6. The method of claim 1 , wherein the mutant COMT polypeptide comprises Ala claim 1 , Arg claim 1 , Asn claim 1 , Asp claim 1 , Cys claim ...

Подробнее
Номер записи: 95
30-04-2020 дата публикации

METHOD FOR PRODUCING ENZYMATIC REACTION BY USING ADENOSINE TO REPLACE ATP

Номер: US20200131551A1
Автор: Liu Hui, Liu Shanshan, QIN Yongfa, ZHOU Wenwen
Принадлежит:

The present invention discloses a production method of enzymatic reaction using adenosine instead of ATP. The method comprises the following steps: (1) adding ATP regeneration enzyme, AK enzyme and adenosine in proportion to carry out an enzymatic reaction in an enzymatic reaction system; (2) separating the ATP regeneration enzyme and AK enzyme by either directly separating ATP regeneration enzyme and AK enzyme immobilized in a reaction tank or separating free ATP regeneration enzyme and AK enzyme by an ultrafiltration membrane in a filter; and (3) separating and purifying the filtrate of step (2) to obtain a product. The disclosed method provides: greatly reduced industrial production costs; faster reaction rate; stable enzyme recovery system that is energy efficient and environmentally friendly; and capability of reusing the byproducts or collecting them for the production of ATP. 1. A production method of enzymatic reaction requiring ATP wherein adenosine in used instead of ATP , the method comprises the following steps:(1) adding ATP regeneration enzyme, AK enzyme and adenosine in proportion in an enzymatic reaction system to carry out the enzymatic reaction;(2) separating ATP regeneration enzyme and AK enzyme from the enzymatic reaction system to produce a filtrate, wherein the ATP regeneration enzyme and AK enzyme is separated from the enzymatic reaction system by a method selected from the group consisting of: directly separating the immobilized ATP regeneration enzyme and AK enzyme and separating free ATP regeneration enzyme and AK enzyme by an ultrafiltration membrane in a filter; and(3) separating and purifying the filtrate of step (2) to obtain a product.2. The method according to claim 1 , further comprising the following steps:(4) recovering the separated ATP regeneration enzyme and the AK enzyme for use in step (1) for the enzymatic reaction; and(5) collecting the ATP, ADP or AMP produced in the enzymatic reaction by a method selected from the group ...

Подробнее
Номер записи: 96
30-04-2020 дата публикации

IVERMECTIN B1B PRODUCING STRAIN AND USE THEREOF

Номер: US20200131552A1
Автор: CHANG Zongming, HUANG JUN, LI Meihong, Li Na, LIN Jiatan, Zhou Jun
Принадлежит: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

Provided are a strain C63-51 with a high yield of ivermectin B1b and a method for producing ivermectin B1b by using this strain. By using the above-mentioned strain and method, efficient production of single ivermectin B1b can be achieved. 1Streptomyces avermitilis. A strain C63-51 , deposited on Dec. 22 , 2016 in the China General Microbiological Culture Collection Center (CGMCC) with an accession number CGMCC NO. 13370.2Streptomyces avermitilis. A composition comprising the strain C63-51 according to .3Streptomyces avermitilis. A method of manufacturing ivermectin B1b or a pharmaceutical composition containing ivermectin B1b comprising using the strain C63-51 according to .4Streptomyces avermitilis. A method of producing ivermectin B1b comprising performing fermentation in a medium containing an assimilable carbon source and/or nitrogen source using the strain C63-51 according to .5. The method according to claim 4 , wherein the assimilable carbon source is one or more of sucrose claim 4 , glucose claim 4 , amylase claim 4 , fructose claim 4 , rhamnose claim 4 , raffinose claim 4 , xylose claim 4 , arabinose claim 4 , industrial molasses claim 4 , lactose claim 4 , galactose claim 4 , maltose claim 4 , trehalose claim 4 , xylan claim 4 , dextrin claim 4 , corn starch claim 4 , sorbitol claim 4 , salicin claim 4 , inositol claim 4 , mannitol claim 4 , glycerol claim 4 , glycine or inulin.6. The method according to claim 4 , wherein the assimilable nitrogen source is one or more of beef extractum claim 4 , yeast extractum claim 4 , yeast extract claim 4 , yeast powder claim 4 , peptone claim 4 , tryptone claim 4 , gluten powder claim 4 , cottonseed meal claim 4 , peanut meal claim 4 , soybean meal claim 4 , dried powder of corn steep liquor claim 4 , bran claim 4 , urea claim 4 , ammonium salt or nitrate.7. The method according to ; wherein the medium further comprises an inorganic salt claim 4 , and the inorganic salt is one or more of MnSO claim 4 , NaMoO claim 4 ...

Подробнее
Номер записи: 97
24-05-2018 дата публикации

Biosynthesis of Phenylpropanoid and Dihydrophenylpropanoid Derivatives

Номер: US20180142216A1
Автор: Beata Joanna LEHKA, Ernesto SIMON VECILLA, Jane Dannow DYEKJAER, Michael EICHENBERGER, Michael Naesby, Niels Bjerg JENSEN, Walden Emil BJØRN-YOSHIMOTO
Принадлежит: Evolva AG

Provided herein are methods and compositions for producing phenylpropanoid derivatives, such as chalcones and stilbenes, and dihydrophenylpropanoid derivatives, such as dihydrochalcones and dihydrostilbenes, in microorganisms. In particular, the disclosure provides recombinant microorganisms and methods of use thereof for producing phenylpropanoid derivative compounds and dihydrophenylpropanoid derivative compounds.

Подробнее
Номер записи: 98
24-05-2018 дата публикации

MUTANT SUCROSE PHOSPHORYLASES WITH IMPROVED GLYCOSYLATION ACTIVITY TOWARDS POLYPHENOLS

Номер: US20180142276A1
Автор: DE WINTER Karel, DESMET Tom, DIRKS-HOFMEISTER Mareike, VERHAEGHE Tom
Принадлежит: Universiteit Gent

The present invention relates to glycosylating polyphenols via biocatalysis. More specifically the present invention discloses particular mutants of the thermostable sucrose phosphorylase derived from the microorganism which efficiently glycosylate polyphenols such as resveratrol. 1. An in vitro method to glycosylate a polyphenol comprising:contacting in vitro a sucrose phosphorylase comprising the amino acid sequence of SEQ ID N° 1, SEQ ID N° 2, SEQ ID N° 3, SEQ ID N° 4 or SEQ ID N° 5 with sucrose or alpha-glucose-1-phosphate, and, a polyphenol, andglycosylating said polyphenol.2. The in vitro method according to wherein said polyphenol is a stilbenoid.3. The in vitro method according to wherein said stilbenoid is resveratrol.4. The in vitro method according to wherein said polyphenol is a flavonoid.5. The in vitro method according to wherein said flavonoid is apigenine claim 4 , hesperetin claim 4 , quercetin or epicatechin6. The in vitro method according to wherein said polyphenol is a phenoxyphenol.7. An in vitro method to glycosylate a polyphenol comprising:contacting in vitro a sucrose phoshorylase with sucrose or alpha-glucose-1 phosphate, and, a polyphenol, and,glycosylating said polyphenol, wherein said sucrose phoshorylase is a fragment of SEQ ID N° 1, 2, 3, 4 or 5 that has at least 90% sequence identity with SEQ ID N° 1, 2, 3, 4 or 5 and wherein said fragment comprises, in addition to having the amino acid A,V,T or G at position 134 of SEQ ID N° 1-4, respectively, or having a deletion at position 134 as shown by SEQ ID N° 5, at least the following 16 catalytic amino acids of SEQ ID N° 6: D49, F52, H87, F157, Q165, R195, D197, A198, Y201, E238, H240, H295, D296, D342, Q345 and R399.8Thermoanaerobacterium thermosaccharolyticum. A variant of the thermostable sucrose phosphorylase derived from the microorganism comprising SEQ ID N° 2 claim 7 , 3 claim 7 , 4 or 5 claim 7 , or claim 7 , comprising a fragment according to . The present invention relates to ...

Подробнее
Номер записи: 99
04-06-2015 дата публикации

TRANS-RESVERATROL POLYSACCHARIDE, METHOD FOR PRODUCING THE SAME, AND COMPOSITION COMPRISING THE SAME

Номер: US20150152130A1
Автор: HAMADA HIROKI, Kojima Shinichi, MOMOTA CHIEMI, TAKAHASHI SHOJI
Принадлежит:

An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. Another object of the present invention is to provide a trans-resveratrol derivative that has no toxicity against cells and has sufficient antioxidative properties and/or a sufficient whitening effect. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin glucanotransferase. 1. At least one trans-resveratrol polysaccharide selected from the group consisting of:trans-resveratrol-3-O-β-D-diglucoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position of trans-resveratrol-3-O-β-D-diglucoside via glycoside linkage;trans-resveratrol-4′-O-β-D-diglucoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position of trans-resveratrol-4′-O-β-D-diglucoside via glycoside linkage;trans-resveratrol-O-β-D-3-diglucoside-4′-monoglycoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position of trans-resveratrol-O-β-D-3-diglucoside-4′-monoglycoside via glycoside linkage;trans-resveratrol-O-β-D-3-monoglucoside-4′-diglycoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G′-4 position of trans-resveratrol-O-β-D-3-monoglucoside-4′-diglycoside via glycoside linkage; andtrans-resveratrol-O-β-D-3-diglucoside-4′-diglycoside, and compounds in which sugar is further linked to the hydroxyl group at the 2G-4 position and/or the 2G′-4 position of trans-resveratrol-O-β-D-3-diglucoside-4′-diglycoside via glycoside linkage.2. The trans-resveratrol polysaccharide according to claim 1 , wherein the sugar is at least one monosaccharide selected from the group consisting of glucose claim 1 , galactose claim 1 , mannose claim 1 , xylose claim 1 , fructose claim 1 , rhamnose ...

Подробнее
Номер записи: 100

©DocSearch.ru 2020-2024